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Abstract
Background: People with diabetes are at increased risk of adverse events, whilst
admitted to hospital. Significant research has characterised this increased risk. There
is also evidence that patients with diabetes are at increased risk, following hospital
discharge; however, much less research has considered this area. This thesis aims to
explore approaches and associations to understanding the risk of readmission and
mortality, when patients are discharged from hospital with diabetes.
Methods: Initial patient public involvement grounded this research in areas that were
most important to patients themselves. A systematic review of known risk factors for
readmission, when patients are discharged from hospital with diabetes, was
conducted. A subsequent comparison was made to risk factors identified in the
literature for mortality outcomes. Extraction of retrospective data was performed for all
adult patients discharged, with a diagnosis of diabetes, from a major UK tertiary
referral centre over a 3-year period. The data extraction and subsequent analysis were
directly informed by systematic review results. Associations between risk factors and
adverse events were identified and evaluated with calculation of effect size statistics.
Results: Forty-seven studies identified statistically significant risk factors for
readmission. This resulted in 72 distinct risk factors divided across 7 separate
categories. Similar categories could be identified when considering mortality
outcomes, however a much smaller number of studies and risk factors were identified.
Analysis of extracted retrospective data identified utility of effect size measures in
evaluating associations, with particularly important associations noted for socio-
economic and biochemistry related factors. Clear associations are reported between
socio-economic status and readmission for patients with T1DM and socioeconomic
status and mortality for patients with T2DM. Hba1c values are further demonstrated
statistically significantly associated with 30-day readmission and 365-day mortality
Discussion: This thesis identifies new knowledge regarding negative outcomes when
patients with diabetes are discharged from hospital. This understanding is important
to developing interventions to reduce such outcomes. Future work will look to
understand causal links between these risk factors and outcomes, as well as







An ancient Greek called Aretaeus, who lived in a country called Cappadocia bordering
the Euphraytes River, is credited as the first person to describe the condition of
diabetes mellitus, in approximately 120AD. His observations noted the condition as
“fortunately rare”; however, he identified that “short will be the life of the man in whom
the disease is fully developed” [20]. Bringing to bear the power of modern medicine,
we have transformed diabetes into a chronic life-long condition, with a myriad of
treatment options, quite different to Aretaeus’ description. Concurrently, however, the
condition can no longer be considered rare, but rapidly increasing in prevalence [21].
Our approach to scientific observation has also dramatically changed and, rather than
considering one individual patient at a time, we have the privilege of using health
informatics methodology to better understand the risks encountered by populations of
patients with diabetes. It is on that foundation that this PhD creates new knowledge of
a condition, first described over 3500 years ago, but of enormous and growing
importance to society in the 21st century.
Our modern definition of diabetes mellitus is that of a “group of metabolic diseases
characterized by chronic hyperglycemia resulting from defects in insulin secretion,
insulin action, or both” [22]. Diabetes mellitus is typically divided into three separate
groupings based on aetiology; Type 1 Diabetes (T1DM), Type 2 Diabetes (T2DM) and
Gestational Diabetes (GDM). This classification was proposed by the American
Diabetes Association in 1997, and later adopted internationally [23].
Type 1 Diabetes Mellitus is considered an immune mediated process, caused by
autoimmune destruction of beta type cells in the pancreas, which produce insulin.
Typically, people with this form of diabetes present earlier in life, during infancy,
adolescence and early adulthood, and rapidly progress to an absolute requirement for
exogenous insulin to survive [24]. The aetiology of T2DM, in contrast, is more
prominently driven by resistance of body tissue to insulin secreted by the pancreas,
albeit with an element of abnormal insulin secretion, which may worsen over time [24].
T2DM typically presents more insidiously, with a period where dietary control alone or
oral medications may suffice in providing adequate control [25]. Newer research is
suggesting aggressive calorie restriction may provide options for diabetes remission
in selected population groups [26]. The third broad category of diabetes mellitus is
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gestational diabetes, which represents the development of glucose intolerance during
the period of pregnancy, which typically (although not always) resolves following
delivery of the foetus [27]. The presence of gestational diabetes is a very strong risk
factor for the subsequent development of T2DM, in later life [28]. It is important to note
that as our understanding of diabetes and, particularly the underlying genetics,
improves, there is increasing blurring between the definitions of diabetes categories,
and identification of specific diabetes subcategories [29]. The classification of diabetes
mellitus by T1DM, T2DM & GDM is however the typical approach to management in
modern clinical practice, and it is on this basis that this PhD thesis is developed [25,
30, 31].
The pathophysiology of diabetes is based around the development of micro and
macro-vascular complications, as a consequence of the hyperglycaemic state [32, 33].
These complications are progressive, over time, and related to the degree of
hyperglycaemia. Macrovascular complications include cardiovascular disease, stroke
and peripheral vascular disease [34]. Microvascular complications include retinopathy,
renal failure and neuropathy [35]. Diabetic foot disease represents a combination of
peripheral vascular disease and neuropathy [36]. We know that the risk of worsening
diabetes complications is affected by a range of factors, including race and social
deprivation [37].
There are felt to be multiple drivers, affecting the impact of race on diabetes and its
complications [38]. These can be broadly divided into biological and non-biological
factors [39]. The greatest focus in the research literature has been in racial differences
for T2DM. Biological factors include variations in obesity, fat distribution, glucose
metabolism and genetic differences different groups. When considering obesity, large
scale studies have demonstrated variations in obesity levels between different racial
groups, with non-Hispanic blacks and Mexican-Americans having some of the highest
levels of obesity [40]. The distribution of that fat is also important, with non-Hispanic
black women having greater levels of fat stored in subcutaneous tissues compared to
non-Hispanic white women who have greater visceral fat storage. This has important
implications on the degree of insulin resistance in each population [41]. The causation
of differences in insulin sensitivity, between racial groups, is felt to be based around
variations in the ability of the body to shift metabolism towards focusing on fat oxidation
or reducing levels carbohydrate metabolism, in response to either dietary input or
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circulating insulin levels [42]. A significant degree of this variation will likely be
attributable to genetic differences, with genetic assassination studies ongoing. A
number of gene associations, varying between different races, have been identified.
These include ELMO1 gene for nephropathy, ADIPQ for coronary artery disease and
VEGF for retinopathy; this is certainly an area where further research is needed [43].
A major non-biological driver in racial variation in diabetes is felt to be the concept of
“Acculturation” [38]. Acculturation can be defined as “the process by which immigrants
adopt the attitudes, values, customs, beliefs, and behaviours of a new culture” [44].
This has been shown to contribute to poorer outcomes with respect to behaviours
known to influence diabetes immigrant populations, albeit potentially mitigated by
variations in socio-economic status. Further behavioural drivers known to vary
between racial groups, with an impact on diabetes care, include physical activity levels
and smoking rates [45]. Importantly, there is also known to be complex variations in
maternal health behaviours that can influence the next generation through epigenetic
changes [38, 46].
There is a close interlink between socio-economic status and racial variations in
diabetes. However, socio-economic status and particularly social deprivation itself can
have a significant impact on diabetes complication risks, independent of race. The
impact of social deprivation is thought to be highest for retinopathy and cardiac-based
complications [47]. A wide range of factors are thought to contribute to the increased
risk in deprived populations. These include increased rates of smoking [48], reluctance
to use insulin [48], co-morbidity burden [48] and reduced use of protective medications
such as lipid lowering statins [49]. Importantly, social-deprivation has been shown to
exert negative influences even from an early life stage, which is particularly important
given nature of diabetes as a chronic disease with accumulation of complications risks
over the life-course of the condition [50].
There are currently 4 million people of all races and socio-economic backgrounds
diagnosed with diabetes in the United Kingdom, with an individual diagnosed with
diabetes on average every 2 minutes [51]. The incidence of diabetes is increasing at
an alarming rate. In England, there is a 5% increase in incidence, annually [52]. The
cost of managing diabetes, and its complications, places significant pressures on NHS
services, with an estimated 10% of the NHS Budget spent on diabetes, thus
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representing an annual cost in excess of £10 billion [53]. The proportional prevalence
of diabetes is particularly high amongst hospital inpatients, with 18% of NHS inpatient
beds occupied by people with a diagnosis of diabetes; this can rise to in excess of
30% in some hospital settings [54]. The diagnosis of diabetes is known to be a
significant risk factor for poor outcomes of patients in hospital, regardless of their
underlying reason for admission [55-57]. There are varied reasons suggested for the
increased risks encountered with patients with diabetes, whilst inpatients. One of the
most prominent risks is that of hypoglycaemia among patients treated with insulin or
other hypoglycaemic agents, such as gliclazide [58]. Patients are also at risk of the
consequences of hyperglycaemia, whilst inpatients, including diabetic ketoacidosis
and increased plasma viscosity, causing deep vein thrombosis [59], stroke or
myocardial infarction [60].
Whilst there has been considerable research, considering the risks of diabetes related
to hospital inpatients, we also know that there are increased risks at the point of
discharge from hospital. Indeed, the cost of excess emergency readmissions, for
patients discharged from hospital, with a co-morbid diagnosis of diabetes, is over £99
million each year [61].
The process of discharge, following an inpatient admission, represents a key step or
transition point during the patient journey. The discharge process is, however, highly
complex and, unlike the admissions process, entry into it is disparate with no unifying
points of entry, such as triage or acute admission units. This has resulted in much less
research into examining the process of discharge from hospital, despite its importance.
In particular, we know that the rate of emergency readmission to hospital has
increased, over the last 5 years, by 23.8% [62]. Readmission rates are known to be
higher amongst medical patients, especially those with chronic diseases, such as
diabetes [63]. Attempts to understand the process have been published for psychiatric
discharges [64], alongside patient and staff perceptions of the discharge process [65,
66]. The complexity of both the discharge process and diabetes care has until now
proved a major barrier to understanding.
Literature characterising the discharge of patients with diabetes is limited, usually
focusing on the failure of discharge; readmission. These sporadic studies are based,
almost exclusively, with US patients and within US healthcare systems [67]. They are
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difficult to compare, because of non-uniformity of definition, including reason for
readmission (index condition vs. any reason), duration of follow-up, planned versus
unplanned, and preventable vs. non preventable episodes, thus preventing
generalisation [67]. More common is the study of diabetes as a predictor of
readmission amongst a number of other medical conditions [68, 69]. A single study,
using UK Hospital Episode Statistics Service (HES) data, has been conducted to
consider the impact of socioeconomic data on diabetes admission and re-admission,
which, although novel in its approach, is severely limited by a small number of
extracted variables and with no adjustment for individual confounders, beyond age
and sex [70]. Diabetes represents a data rich pathology, which facilitates investigation
beyond just “readmission rates”, with glycated haemoglobin (Hba1c) being a further
outcome measure to consider, following hospital discharge [71].
In recent years, healthcare has undergone an information technology revolution
through the digitization of medical records [17]. This has created large amounts of
routinely collected data with enormous research potential. Effectively representing a
by-product of clinical care, these data include quantitative (e.g., laboratory values),
qualitative (e.g., text-based documents), and transactional data points (e.g., a record
of medication delivery) [17]. Diabetes, in particular, represents a data rich pathology
with extractable information on glycaemic control, renal function, cardiovascular
function, foot and eye health [6]. Whilst this information represents an important
opportunity to improve the quality and efficiency of care, it requires an understanding
of how to process and utilise such complex information. An integrated clinical
informatics approach to analytics and evidence building is needed, which until this time
has been limited in application [72]. A successful integrated clinical informatics
approach represents the transition of large data repositories into meaningful
processes and policies that improve the efficiency and quality of care delivered [73].
Healthcare as a sector lacks the skills and experience to achieve this within a short
time frame; translational research across academic departments and industrial sectors
will open new research approaches and methodologies to healthcare [74].
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1.2 Gap in current evidence
Therefore, there exists, overall, a significant gap in the current evidence regarding our
understanding of risk factors for patients with diabetes, when they are discharged from
hospital. Two of the most important risk factors, when patients with diabetes are
discharged from hospital, are the increased risk of readmission [63] and the high risk
of mortality [75]. This evidence gap exists despite the increased availability of routinely
collected clinical data, which could provide insight into associations, risks and risk
factors for this population group [6]. This gap, in the research, is important, as by
developing an understanding of what contributes to these risks, we know from other
conditions we can then develop both risk prediction tools to identify patients at the
highest risks and design/test interventions to reduce risk [76].
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1.3 Patient Public Involvement & Public Engagement
It is important to involve patients and the public in research, particularly when research
uses healthcare data and relates to health outcomes. In particular, patient public
involvement aims to improve the appropriateness, acceptability and relevance of
research, and also ensures that the research focuses on issues that are important to
patients, rather than issues that are important to the public [77]. Typical Patient Public
Involvement (PPI) research does not involve large numbers of participants and is
typically qualitative in nature. However, it is the quality of the interaction with those PPI
representatives that defines the success of PPI [78].
This PhD research has been guided by PPI based activities. The gap in the current
evidence described above is an important gap for patients themselves. The
subsequent development of the research question and research area was supported
by working with the Diabetes UK. Initially, the author liaised with the regional Diabetes
UK Office, who suggested speaking directly to the national “Diabetes Voices”
programme. This programme, hosted by Diabetes UK, comprises voices from
Diabetes UK members across the United Kingdom, who respond to questionnaires
and surveys used to develop diabetes based services and research. Respondents are
typically both those with diabetes and also their carers. Working with the Diabetes
Voices Team, we co-developed a survey to members of this group. This survey is
shown below in figure 1.1. Six responses were received to the survey. Some examples
of the narrative responses to the survey are included below, which clearly highlight the
importance of this area of research:
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Overall, the national survey based PPI work highlighted a number of key elements
important to this work:
1) Patients see hospital discharge as a distinct process in their journey, more so
than doctors.
2) Current approaches to hospital discharge are poor and do not support patients
sufficiently.
3) The key to improving the discharge for patients with diabetes is providing them
with the information that they need, which must be personal to them.
This preliminary patient public involvement research identified that the proposed
thesis’ research area is one of significant importance to patients, and that working to
provide the evidence base for better information provision would be beneficial. The
author of this thesis subsequently worked with the National Institute of Health
Research (NIHR) Research Design Service to submit a PPI Funding Request, which
was successful. This enabled the recruitment to recruit of 3 PPI members, through the
“NIHR People In Research Network” to allow a more detailed critique and evaluation
of this thesis’ proposed research approach. Three PPI members were recruited, who
each brought a different perspective to the PPI work based on their age, location and
underlying diagnosis. Communication with these PPI members was both through
email and telephone conversation. This helped shaped the targeting of outcome
measures looking at readmission and mortality with consideration of glycosylated
haemoglobin (Hba1c), being important and relevant measures for the PPI members
and ones that this research has subsequently adopted.
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Figure 1: Diabetes UK Voices Survey Questionnaire
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1.4 Overall Aim & Research Objectives
Diabetes is an important condition increasing in prevalence. In the context of a multi-
morbid population, it is important we utilise existing data to better understand risks for
this population of patients. This thesis builds on the identified research gaps regarding
the risks, when patients are discharged from hospital with a co-morbid diagnosis of
diabetes.
1.5 Research Aim
This thesis aims to explore approaches and associations to the risk of readmission
and mortality, when patients are discharged from hospital with an existing diagnosis
of diabetes mellitus.
1.6 Hypothesis
From the above aim, the following hypothesis is formulated: Risk factors for
readmission and mortality can be identified for patients being discharged from hospital
with a diagnosis of diabetes, and these can be demonstrated through interrogation
and analysis of the electronic patient record.
1.7 Research Objectives
To achieve this aim and test this hypothesis, the following objectives have been
identified:
1) Identify what risk factors for the readmission of patients with diabetes can be
identified from the existing research literature. This is explored through the
systematic review, presented in Chapter 3. [RO1]
2) Describe how the research literature differs regarding risk factors for
readmission compared to risk factors for mortality, for patients being discharged
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from hospital with diabetes. This is explored through the comparison between
two systematic reviews, presented in Chapter 4. [RO2]
3) Demonstrate how standardised effect sizes can be used to understand factors
associated with readmission for people with diabetes, including comparisons
between cohorts and risk factors. This is presented in Chapter 5 and further
elaborated in Chapters 6 & 7. [RO3]
4) Identify what associations exist between socioeconomic geography and poor
outcomes for people being discharged from hospital with a diagnosis of
diabetes? This is explored in Chapter 6. [RO4]
5) What is the association between glycaemic control and outcomes for patients
being discharged from hospital with a diagnosis of diabetes? This is explored
in Chapter 7. [RO5]
1.8 Thesis Structure
This PhD is structured according to the University of Warwick Doctoral College
Guidelines. The introductory section establishes the context for the research and a
clear aim and set of objectives, this is followed by a detailed methodology chapter.
Subsequent chapters incorporate two systematic reviews and three experimental
chapters, which directly meet the research objectives outlined. Each chapter cross
references these research objectives and relates to the new knowledge generation
summary. The experimental chapters consider the use of standardised effect size
measures, the impact of socio-economic status on outcomes and finally an analysis
of biochemistry values on patient outcomes. The final elements of the thesis bring
together the learning through a detailed discussion section and overall conclusion.
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1.9 New Knowledge Generation
This research directly creates new knowledge regarding the association between risk
factors and outcomes for patients being discharged from hospital, with a diagnosis of
diabetes. The new knowledge generated includes:
1) A systematic understanding of known risk factors for readmission in the
currently published research literature [9].
2) A systematic understanding of differences, in the systematic research literature,
between risk factors for readmission and mortality for patients being discharged
from hospital with a diagnosis of diabetes [10].
3) New knowledge regarding the strengths of association between different risk
factors identifiable from a typical electronic health record, for different cohorts
of patients being discharged with diabetes and in relation to different outcomes
[7, 11, 12].
4) New knowledge regarding the association between socioeconomic geography
and negative outcomes, when patients with diabetes are discharged from
hospitals with diabetes [13, 14] .
5) New knowledge regarding the association of glycaemic control and time to
testing with poor outcomes when patients are discharged from hospital with a
diagnosis of diabetes [15].
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Chapter 2: Study Design
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2.1 Rationale for Study
This PhD aims to use routinely collected electronic patient data, to form the foundation
of developing new knowledge regarding the risks associated with negative outcomes
when patients are discharged from hospital, with a diagnosis of diabetes. This
understanding will help inform both clinicians and patients themselves, regarding risks
when being discharged from hospital, whilst also supporting the development of
targeted interventions. Furthermore, the new knowledge generated, during this PhD,
will enable further research work that develops rigorous risk prediction models for
patients being discharged from hospital with a diagnosis of diabetes. These risk
prediction models will enable policy makers and clinicians to target limited resources
to those patients at the highest risk of poor outcomes, when discharged with a
diagnosis of diabetes. Therefore, it is essential that this research is performed prior to
attempting to develop risk prediction algorithms without a firm pre-specified evidence
based foundation. Indeed, algorithms for identifying patients at risk of readmission
have been published [79, 80]. These describe multivariate logistic regression
approaches, applied across all diseases/specialisms (not focused on one condition or
group of conditions e.g., diabetes). Despite (or perhaps because of) the broad patient
population included, they only considered a small fraction of factors postulated to be
implicated in the discharge process [81, 82]. Consequently, these studies report only
a limited predictive capacity, with area under the receiver operator curve (AUC) values
of 0.65 to 0.68, with no other studies demonstrating better predictive capacity to the
best knowledge of the author. The AUC is recognized as “the measure of a diagnostic
test’s discriminatory power” [83], where a value of 1.00 represents a theoretically
perfect test, and a value of 0.5 representing no discriminative value [83]. Developing
a better understanding of pre-specified factors, associated with negative outcomes in
a condition specific manner, may support the future development of more effective risk
prediction models. Based on this rationale and ambition a research approach was
designed by Dr Robbins, which is described in the next section.
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2.2 Study Design & Research Approach
The overall study design approach is demonstrated visually in Figure 2 below. The
design is grounded on the foundation of two systematic reviews presented at the start
of this thesis. The systematic reviews are highlighted in blue representing their
importance to the research approach. A systematic review can be defined as “A type
of research synthesis that are conducted by review groups with specialized skills, who
set out to identify and retrieve international evidence that is relevant to a particular
question or questions and to appraise and synthesize the results of this search to
inform practice, policy and in some cases, further research [84].“ High quality
systematic reviews should be conducted in accordance with the “Preferred Reporting
Items for Systematic Reviews and Meta-Analyses” (PRISMA) statement [85]. This is
a checklist and flow diagram that helps authors improve the reporting of systematic
reviews and meta-analysis. A particularly important element of the PRISMA approach
is the assessment of paper quality. In this thesis, the approach to quality assessment
is fully described in Chapter 4 and incorporates both the quality assessment
approaches described in PRISMA and the 5 C’s (category, correctness, context,
contribution & clarity) approach, promoted by S.Keshav and routinely used in the
engineering and computing literature reviewing [86]. Both systematic reviews are
performed and described in accordance with the PRISMA statement and include
rigorous quality assessment.
The first systematic review in this thesis considers risk factors for readmission, when
a patient is discharged from hospital with diabetes, and forms chapter 3 of the thesis.
The chapter directly answers the first research question described above: “What risk
factors for the readmission of patients with diabetes can be identified from the existing
research literature?”. In doing so, directly collates new knowledge from the existing
research literature.
The third thesis chapter considers the second research question: “How does the
research literature differ in regarding risk factors for readmission compared to risk
factors for mortality for patients being discharged from hospital with diabetes?”. The
chapter presents the results of a systematic review considering mortality and hospital
discharge for patients with diabetes and compares this, in detail, with the results of the
first systematic review, which considers readmission. For both review chapters, a
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decision was made not to perform a meta-analysis. A meta-analysis can be defined
as “a statistical procedure that integrates the results of several independent studies
considered to be ‘combinable’ ” [87]. The studies, identified during the literature review
and described in the relevant chapters, are too varied and diverse to be readily
“combinable” into a meta-analysis. This is a likely consequence of the early stage
nature of the research literature in this area, as explored later in this thesis.
However, the two systematic reviews are important, because the knowledge
generated from these review chapters subsequently informs the data extraction
process for the thesis. These extracted data form the basis of the next three
experimental research chapters presented in this thesis.
The diagnosis of diabetes was taken from the coding of patients at discharge and,
thus, if there was discrepancy in the diagnosis within the record, the latest diagnosis
of diabetes at discharge was used. Maternity patients were excluded from the study,
due to the differing nature of maternity care and readmission patterns. Patients,
discharged within the last 6 months of the study period, were not evaluated as index
patients, to ensure that all patients had a full period of 6 months follow up on the
electronic health record, in order to assess for the outcome measures of interest.
These data are used in the fourth chapter of this thesis to answer the research
question “How can standardised effect sizes be used to understand factors associated
with readmission for people with diabetes, including comparisons between cohorts and
risk factors” and generates new knowledge regarding the strengths of association
between different risk factors identifiable from a typical electronic health record for
different
The fifth chapter of the thesis represents the first assessment of the impact of
socioeconomic status on the risk of readmission and mortality, at the point of discharge
from hospital for people with diabetes. It, therefore, directly considers the research
question “What associations exist between socioeconomic geography and poor
outcomes for people being discharged from hospital with a diagnosis of diabetes?”
The chapter presents exciting new findings on the differential impact of socioeconomic
status on different pre-specified cohorts of patients with diabetes.
The final experimental chapter (chapter 6) represents a more exploratory piece of
research, looking to better understand the research question posed around the use of
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glycaemic control on outcomes, when patients with diabetes are discharged from
hospital. In this chapter, the impact of glycated haemoglobin, both prior to and
following discharge, in relation to outcomes of interest is considered. This chapter
directly creates new knowledge, based on the use of Hba1c measures; but also leads
the way for future research, when wider data are either available on new measures of
glycaemic control, including continuous blood glucose monitoring and interstitial
glucose monitoring.
The discussion chapter brings together these themes, highlights the strongest
associations with the outcomes of interest alongside a detailed description of the
strengths and limitations of this research approach. In particular, the discussion
chapter extends the discussions of future work proposed in chapter 6, considering how
the new knowledge generated within this research can be used as the foundation for
the development of automated risk predication tools that directly support the
improvement of clinical care outcomes. Included within this chapter is a discussion
regarding recommendations about how the work could be used to inform: a) the
healthcare service (i.e. how discharge could be improved by future follow-up work), b)
health informatics (i.e. what health IT professionals can learn about better supporting
similar studies in the future, and c) the clinical impact and exploitation of the results of
this study (i.e. the work provides some solid early results about risk factors).
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Figure 2: Summary of research design & approach
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2.3 Research Data & Context
Routinely collected respective data were extracted from University Hospitals Coventry
& Warwickshire NHS Trust (UHCW). Data were extracted for all adult (aged 18 or
over) patients discharged from UHCW with a diagnosis of diabetes, over a 3-year
period from October 2014 to October 2017. The variables extracted were informed
based on the systematic literature reviews and are described in more detail in chapters
3 & 4. Outcome variable data were extracted for hospital readmission and mortality.
Data were extracted by UHCW’s Performance and Programme Management Office
(PPMO) for the requested variables from the Clinical Results and Reporting System
(CRRS) used at UHCW and anonymised before being passed to the researcher Dr
Tim Robbins. The CRRS system is a bespoke “home-grown” electronic health record
[88] designed and developed in house at UHCW. The PPMO enabled extraction
approach follows the robust methodologies used by the Trust to extract and submit
data to both the Care Quality Commission [89] and NHS England. This data extraction
approach from CRRS has been used in a broad range of research studies [90-92].
Due to the ethical restrictions the author was unable to interrogate the electronic health
record system directly. Patients were identified based on coding of diabetes on
discharge letters, with the coding system used relating to the ICD-10 codes E10
(Insulin dependent diabetes), E11 (non-insulin dependent diabetes), E12 (malnutrition
related diabetes mellitus), E13 (other unspecified diabetes mellitus), (E14 (unspecified
diabetes mellitus). These codes were selected based on the broad coverage all
potential codes used when patients with diabetes were discharged from hospital. The
limitation associated with this approach are discussed in more detail in Chapter 8.
The data extracted included 55,826 discharges, with a mean average patient of 66.5
years (median 69, Inter-quartile range 12). There were 5117 discharges for patients
with T1DM and 47786 for patients with T2DM. 53% of patients were male. The mean
average length of stay was 4.16 days.
University Hospitals Coventry & Warwickshire NHS Trust is a major 1174 bed tertiary
referral centre in the West Midlands region of the United Kingdom. The trust provides
acute inpatient care and treatment for specialties including cardiology, cardiothoracic
surgery, care of the elderly, dermatology, diabetes, ear nose and throat,
gastroenterology, gynaecology, haematology, neonatal intensive care, nephrology,
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neurology, oncology, ophthalmology, plastic surgery, renal medicine, respiratory
medicine, rheumatology, stroke, and urology. The Trust has approximately 151,028
inpatient admissions per year, with 918,932 outpatient appointments and 236,620
accident and emergency attendances [93].
The population served by this organisation is very diverse. There are 366,800 people
living in Coventry, representing the second fastest 10-year growth rate of all local
authority areas, outside of London. It is felt the primary driver for this population growth
is international migration. Coventry’s population has a younger profile than England in
general with an average age of 32.1 years compared to 39.9 years across England
[94]. The latest census reported that 66.6% of Coventry’s population is White British
compared to a West Midlands average of 79.2% and national figure of 79.8%. The
second largest ethnic group, in Coventry, is Asian British (16.3%), followed by White
Other (7.2%) [95]. It is important to note when considering obesity research that this
is an area with high levels of obesity, with Public Health England estimating that 64.8%
of the adult population in Coventry are overweight or obese [96].
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2.5 Ethical Approval
The research and methodological approach uses routinely collected anonymised
patient data to build an understanding of factors associated with poor outcomes when
patients are discharged from hospital with a diagnosis of diabetes. The research
approach was approved by the University of Warwick’s Biomedical & Scientific
Research Ethics Committee (BSREC) [Study Ref: REGO-2017-2114] and University
Hospital Coventry & Warwickshire NHS Trusts Governance Arrangements for
Research Ethics Committees Process (GAFREC) [Study Ref: GF0220]. The ethical
approvals are included in Appendix 4.
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Chapter 3: Systematic review of risk factors for
readmission of patients with diabetes
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3.1 Introduction
People admitted to hospital have higher rates of diabetes than the general population.
In the United Kingdom, 17% of inpatients have a diagnosis of diabetes mellitus [97].
Irrespective of the initial reason for admission, inpatients with diabetes act as a distinct
cohort of patients with shared risk factors for adverse events [98]. People with diabetes
are at a significantly increased risk of readmission, following discharge [63, 99].
Hospital readmissions rates are a psychological and physical burden to patients, and
a financial burden on healthcare systems [100]. Despite the importance of readmission
amongst people with diabetes, there has been limited research in this area [101].
Specifically, no published studies have attempted to identify, in a systematic way, risk
factors relating to readmission for this cohort of patients.
Understanding risk factors relevant to patients, discharged from hospital with diabetes,
is important to patients, carers, healthcare practitioners and researchers. It supports
the delivery and development of individualised medicine, based on each patient’s
underlying risks; supports our understanding of regional variations in readmission risk;
and supports development of evidence based interventions, targeted at reducing
readmission risks [102]. Interestingly, the paucity of research in this area, for diabetes,
is in direct contrast to other medical conditions, such as heart failure [103]. The
systematic identification of risk factors known to be relevant to patients with diabetes
is important also for this PhD thesis, as it provides a foundation for subsequent data
extraction and analysis (Chapters 5 to 7), ensuring that the process is pre-specified
rather than a random amalgamation of possible risk factors.
This chapter therefore aims to identify, systematically, known risk factors for
readmission to hospital, among people with diabetes. The intention of the study is to
cast a ‘broad net’, ascertaining all known risk factors, irrespective of whether identified
for a specific subset of patients (such as emergency admissions only) or generalised
populations of all inpatients with diabetes.
This knowledge will be essential to the planning of future diabetes services, at both an
inpatient and community level [101]. This is because it will provide potential targets for
improving care, reducing readmission and reducing costs. Readmissions, in particular,
are very costly to the healthcare service and expose patients to the risks associated
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with hospitalisation for a second time [104]. Identifying a comprehensive list of
literature-derived risk factors further facilitates the development of robust pre-specified
risk prediction tools. Effective risk prediction models will enable scarce resources to
be targeted to patients with the greatest need. Overall, it is hoped that a better
understanding of risk factors for people with diabetes will enable the development of
discharge planning that is more effective, better patient education interventions,
improved risk stratification tools and more targeted interventions [102].
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3.2 Methods
The systematic review was conducted according to the PRISMA standards [85]. The
study protocol was published in advance on the PROSPERO database (Registration
Number CRD42017073773). The PROSPERO database is an international
prospective register of systematic reviews aimed at reducing duplication and reporting
bias. PROSPERO is funded by the UK NIHR and run by the Centre for Reviews &
Dissemination at the University of York [105].
Search Strategy
A literature search was performed using EMBASE & MEDLINE databases. The search
terms selected were “diabetes” AND “readmission.” The search strategy included
papers published between August 2006 and August 2018; this wide date range was
to ensure that the extracted studies represented current clinical care practices, given
historically elongated lengths of stay and differing discharge practices. All study
designs were included, with studies limited to English language articles. Due to
differing obstetric and paediatric care practices, articles were restricted to adult, non-
obstetric patient cohorts. Hand searching of references was performed to identify
additional studies for inclusion.
Study Selection
An initial review of all studies, identified by the literature search, was completed by two
authors, the leading author was the author of this thesis. Abstracts and titles were
reviewed; those papers, not including information regarding risk factors for
readmission to hospital in people with diabetes, were removed from the selected
studies. Any discrepancies in article selection would be resolved by discussion,
involving a third author to maximise the rigour of the approach. However, the work was
led by this thesis’ author. All studies selected after the initial screening were reviewed
as full text articles, with exclusion of those that did not identify risk factors for
readmission, did not consider diabetes, or solely considered diabetes as a risk
factor for another condition.
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Data Extraction & Quality Assessment
Data were extracted to a pre-piloted data collection form (Appendix 5). The pro-forma
collected information based on the country within which the study was conducted;
whether the study was collected at a local, regional or national level; the extent of
inpatient data sources, compared to community or social care data sources; the subset
of patients with diabetes included in the study; risk factors that were found to be
statistically significantly associated with readmission, alongside risk factors that were
identified, but not tested for statistical assessment. Data were collected on the
definitions of readmission used by different authors, in particular the time periods
elapsed between admission and discharge, alongside an evaluation of approaches
used to assess effect sizes of the risk factors identified. Data also collected on
Keshav's “5 C’s”, an approach to reviewing journal articles used by the engineering
and computing research community and therefore highly relevant to research articles
considering extraction of data from clinical information systems [86]. The 5 C’s include;
1) Category: What type of paper is this
2) Context: Which other papers is it related to?
3. Correctness: Do the assumptions appear to be valid?
4. Contributions: What are the paper’s main contributions?
5. Clarity: Is the paper well written?
Quality assessment for each of the selected papers was performed according to the
PRISMA Statement approach. This quality assessment was summarised through the
5 C’s approach and included consideration of sample size, evidence to justify the
sample size, appropriateness of any statistical tests applied, study recruitment and
assessment, with overall narrative assessment of quality. The aim of this review is to
assess the state of the literature regarding currently understood risk factors for
readmission of people with diabetes, and thus no studies were excluded based on low
study quality; rather a description of study quality is provided within the results section.
Data Synthesis
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The diversity of definitions of readmission used in the research literature, alongside
diverse subsets of people with diabetes in different studies, precludes any attempt at
meta-analysis. Rather, a narrative summary of risk factors identified was extracted,





The database search strategy identified 1562 articles, with an additional 10 articles
identified through manual reference searching. Following abstract-based screening, a
total of 122 articles were included for full text extraction and review. Forty articles were
excluded following full text review, with 82 studies remaining for full analysis. The























Figure 3: Flow diagram of selected studies
3.3.2 Study Characteristics
From the 82 studies identified, 69 (84%) adopted a retrospective database study
design, 2 articles described non-randomised controlled studies, with a single
randomised controlled trial. There were 2 prospective pilot studies, 3 prospective
cohort studies, 2 case control study, one qualitative study, one systematic review and
one narrative review.
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The majority of studies were based on patient data from the United States of America
(54 studies – 66%), with 9 studies (11%) utilising patient data from the United
Kingdom. The remaining studies were conducted based on patient data from
Denmark, Australia, Taiwan, Canada, China, Brazil, Italy, Israel, Japan, Saudi Arabia
and Spain. One study did not clearly describe the country of origin of the patient
population studied. The timing of the studies is shown in Figure 3 below, with a general
increase in the number of studies published over time.
Figure 4: Number of studies published over time
Studies were predominantly conducted utilising data from a single centre (34 studies,
41%), with 18 studies (22%) utilising data from multiple centres within a single region,
and 26 studies using data from a national database (32%). The study setting was
unclear in two studies, and not applicable to the review articles. Studies predominantly
used inpatient electronic health record sources (68 studies, 83%), with 5 studies (6%)
utilising patient data from primary care or community sources and 8 studies (10%)
using a combination of both community and inpatient data sources.
Forty-seven studies identified statistically significant risk factors for readmission. The
characteristics of these studies are listed in Table 2 & 3; 19 studies identified risk
factors in generalised populations of patients with diabetes (Table 2) and 28 studies
identified risk factors for specific sub-populations of patients with diabetes (Table 3).
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studies, including duplicates, with a mean average of 5.62 statistically significant risk
factors identified per study. When duplicates were removed, we collated 72 distinct
risk factors, for readmission of people with diabetes, from the published literature. A
full breakdown of risk factors, identified during the data collection process, is shown in
Table 4. The risk factors are divided into whether they were identified for only a specific
subpopulation of people with diabetes, or whether they were identified for generalised
diabetes populations.
From the studies identifying statistically significant risk factors, there were 12 different
definitions of readmission used, ranging from 7-days from index hospital discharge, to
5-years from index hospital discharge. The studies, in Table 2 and 3, are ordered by
this readmission definition.
In addition to those risk factors found to have a statistically significant impact on
research, 19 papers identified risk factors that had an impact on outcomes but did not
reach statistical significance. This represented a total of 39 risk factors for
readmission, 11 of which were unique and not identified in the list of risk factors
recognised as statistically significant. These are outlined in Table 5. None of the 19
studies, identifying these non-significant risk factors, reported a power calculation to
ensure they had a sufficient patient population to identify significance, if present.
3.3.3 Study Quality
Studies typically had large sample sizes of patients, with a median average sample
size of 6603 patients. Seven studies, however, included less than 100 participants
[107-113]. All quantitative studies described the statistical approach taken to analysing
data, and these were appropriate to the study design. One quantitative study did not
complete any statistical significance testing [114]. Generally, there was a failure to pre-
specify which risk factors would be assessed as primary or secondary outcomes
measures, and thus providing any justification for the selection of these studies. Of
central importance, only 2 studies (4%) described or provided the results of a power
calculation, in order to justify the sample sizes used and relevance of the subsequent
statistical tests. One study was unclear regarding their description of patient
recruitment and subsequent patient characteristics [115].
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From the studies that identified statistically significant risk factors, 95% reported an
effect size related to the risk factors identified. The effect size is “magnitude of the
difference between groups” and can be reported in standardised or non-standardised
forms [116]. All effect sizes in the extracted papers were reported using non-
standardised statistical methods (typically Odds Ratio [117] or Hazard Ratio [118]),
rather than standardised effect size measures (such as Cohen’s D [119] or Phi [120]).
There was a single qualitative study [107], which was rigorously performed with semi-
structured interviews and thematic analysis. It, however, was restricted to a single
(urban) centre. Twenty-three studies were conducted only in a single centre,
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 51 of 155
Risk factors for specific diabetes subpopulations Risk factors identified in general diabetes population
Risk factor Number of studies & Ref Risk factor Number of studies & Ref
Demographic
Age 4 [142, 143, 146, 149] Age
9 [121, 123, 128, 129, 131, 133-
136]
Race 4 [126, 143, 144, 150] Race 5 [70, 129, 131, 132, 134, 135]
Sex 4 [142, 146, 149, 159] Sex 3 [115, 135, 136]
Marital status 2 [144, 153] Marital status 1 [131]
Socioeconomic status
Insurance type 2 [144, 146] Insurance type 5 [121, 132-135]
Education level 1 [144] Neighbourhood affluence 2 [70, 135]
Employment status 1 [144] Urban home environment 2 [130, 135]
Employment status 4 [121, 124, 131, 133]
Education level 1 [131]
Lifestyle
Illicit substance use 2 [126, 157] Illicit substance use 3 [115, 128, 134]
Smoking status 2 [140, 147]
Geographic location 1 [146]
Patient medical factors
Co-morbidity 5 [138, 140, 143, 146, 160] Mental illness 6 [115, 123, 128, 131, 134, 135]
Insulin dependent diabetes 2 [139, 141] Co-morbidity
10 [115, 121, 123, 125, 128,
131, 133-136]
Macro/microvascular disease 2 [140, 143, 144, 153] Previous admission 5 [123, 124, 131, 134, 135]
Mental illness 2 [143, 144] Macro/microvascular disease 2 [124, 131]
Raised Body Mass Index 2 [143, 149] Hypogylcaemia admission 1 [127]
Hypertension 2 [147, 149] Family history of diabetes 1 [133]
Previous DKA 1 [144] Prior diabetes screening 1 [133]
Previous admission 2 [144, 145] Disability index 1 [136]
Cognitive impairment 1 [142] Cognitive impairment 1 [136]
Falls 1 [142] Body mass index 1 [131]
Previous DKA 1 [131]
Inpatient Stay Factors
Active case management 1 [152] Length of stay 7 [123, 131-135, 142]
Distance from hospital 1 [144] Diabetes specific admission 1 [142]
Surgical procedure type 1 [154] Diabetes education 2 [111, 132]
Penalty if re-admitted 1 [143] Discharge destination 3 [123, 131, 135]
Support post-discharge 1 [143] Distance from hospital 2 [124, 131]
Cardiovascular admission 1 [145] Failure to adhere to guidelines 1 [122]
Diabetes specific admission 1 [145] Hypoglycaemia 3 [129, 135, 136, 142]
Inpatient blood transfusion 1 [144] Failure to record DM diagnosis 1 [126]
Enteral/parenteral nutrition 1 [144] Hospital type 2 [121, 133]
Most extreme blood glucose 1 [144] Previous emergency care use 2 [142, 146]
Intensive care admission 1 [144] Cardiovascular admission 1 [142]
Glycaemic variability 1 [148] Total cost of index hospitalisation 1 [133]
Discharge care management 1 [160] Admitted via emergency depart 1 [134]
Medication related
Combined PPI & clopidogrel 1 [151] Sulfylnourea exposure 2 [131, 135]
Discharge on antibiotics 1 [140] Insulin use prior to admission 2 [124, 131]
Medication non-compliance 1 [126] Statin exposure 2 [128, 131]
Number of prescribers 1 [145] Insulin during admission 2 [128, 136]
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Risk factors for specific diabetes subpopulations Risk factors identified in general diabetes population
Risk factor Number of studies & Ref Risk factor Number of studies & Ref
Thiazolidonide exposure 2 [144, 156] Glucocorticoid exposure 2 [131, 136]
Insulin exposure 4 [144, 155, 158, 162] Thiazolidonide exposure 1 [131]
Glucocorticoid exposure 1 [144] Antihypertensive exposure 1 [131]
Statin exposure 1 [144] Metformin exposure 1 [131]
Sulfylnourea exposure 2 [144, 153]
Anti-hypertensive exposure 1 [144]









Hba1c 2 [138, 149] Hba1c 2 [131, 132]
Fructosamine level 1 [161] Admission raised haematocrit 2 [124, 131]
Electrolyte abnormalities 1 [144] Electrolyte abnormalities 3 [124, 128, 131, 136]
Serum cholesterol 1 [149] Serum Cholesterol 2 [128, 131]
Admission elevated WBC 1 [144] Admission elevated WBC 1 [131]
Serum haematocrit 1 [144]
Serum albumin 1 [144]
Table 4: Statistically significant risk factors identified
Additional risk factors with non-significant impact on readmission rates Article ref
Number of primary care physicians [143]
Living alone [143]
Alcohol use [163]
Failure to attend clinic appointment [163]
Use of variable rate intravenous insulin infusion during admission [108]
Immigration status [164]
Elevated transaminases [140]
Number of clinic visits [128]
Absence of multidisciplinary team input at point of discharge [110]
Type of beta-blocker drug [165]
Type of community practice [146]
Body mass index [144]
SGLT2 exposure [166]
Insulin type [167]
Table 5: Additional risk factors with non-significant impact on readmission rate
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3.4 Discussion
Reducing readmission risk, following hospital discharge, is a key priority for patients
and policy makers across healthcare systems. People with diabetes are at an
increased risk of hospital readmission. This chapter, when published, represented the
first review of its kind, aiming to identify, in a systematic way, risk factors for
readmission to hospital, amongst both generalised and specific populations of people
with diabetes. A total of 72 distinct statistically significant risk factors were identified,
with the most commonly identified being co-morbidities (15 studies), age (13 studies),
race (9 studies), insurance type (7 studies), sex (7 studies). A requirement for insulin
was a widely reported risk factor either before admission, during admission or
subsequent to discharge.
The research literature remains at a relatively early stage of maturity, with the majority
of studies representing retrospective reviews of local or regional datasets. The
research is dominated by studies from the USA, which itself has a unique insurance-
based approach to healthcare, and thus may not be representative of readmission
patterns in other countries.
There were only two review articles that considered risk factors for readmission, one
study was for a particularly specific subset of patients following cardiac surgery [168],
and the other a narrative review article considering generalised diabetes readmission
and preventions opportunities [101]. One study took a qualitative approach to data
collection [107]. Given the nature of diabetes, as a disease of self-management, it is
important that we gain a greater qualitative understanding of factors affecting
readmission. The absence of qualitative studies may explain the relative paucity of
psychological and patient-educational factors in the list of statistically significant risk
factors extracted into Table 4.
The methodological and statistical approaches, to identifying risk factors, are also at
an early stage of maturity. Whilst studies have relatively large sample sizes, there was
rarely any attempt to identify the required sample sizes to meet significance testing
through appropriate power calculations. This may explain the relatively low average
number of statistically significant risk factors identified per study. It is a particular
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concern that, this approach to statistical planning for studies may mean that a number
of risk factors, which could be statistically significant, where an appropriate sample
size was selected, could have been missed. The underlying variation in the patient
populations described (both in the generalised patient populations and specific patient
populations), alongside significant variation in the definition of readmission and use of
unstandardised effect size statistical tools, precludes a meaningful quantitative meta-
analysis of the effect sizes described, in order to create a “hierarchy” of risk factors, or
to assess the consistency across studies identifying the same risk factors. The further
comprehensive, quantitative evaluation of risk factors, will be essential to better
understanding and modifying the risk factors, most relevant to patients discharged
from hospital with diabetes. This thesis begins this process in chapters 5,6 & 7, directly
creating new knowledge in this area.
The risk factors acknowledged in this review, demonstrate a truly diverse set of factors
that significantly contribute to readmission risks in patients with diabetes. Interestingly,
relatively little overlap exists between studies, with 30 risk factors (42%) being
identified in just one study. Risk factors are relatively evenly distributed across the
demographic, socio-economic, lifestyle, patient medical, medication related and
pathology result categories described above. Forty percent of risk factors (29 risk
factors) were identified in both studies examining a subset of populations with
diabetes, and those identifying risk factors for generalised populations of patients with
diabetes. This overlap potentially raises the argument that people with diabetes can
be treated as a distinct population within the inpatient setting.
This review approach has a number of strengths including pre-registration in
PROSPERO; a clearly defined, two-person search across multiple databases;
assessment of study quality; semi-quantitative data synthesis; and patient and public
involvement demonstrating the research question as a priority for patients. There are,
however, a number of limitations that should be considered, including the fact that the
review only considers English Language papers. There is also a potential limitation in
the grouping of risk factors identified as statistically significant in Table 4; for example,
mental health diagnoses have been grouped separately, whilst some might argue they
could be considered together. The groupings have, however, been decided across the
research team, and individualised references provided to support future researchers.
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Concluding Remarks
This chapter identifies a number of key research priorities to better support patients at
discharge from hospital with diabetes. Many of the studies reported mortality outcomes
following discharge alongside readmission outcomes, and it will be important to assess
the extent to which the research literature has considered mortality outcomes, given a
lack of systematic review in this area. This is explored further in Chapter 4. Similarly,
the inability to perform a quantitative meta-analysis of effect sizes, related to individual
risk factors identified, demonstrates and important gap in the research literature.
Taken together, the literature demonstrates that risk factors can, and have in certain
circumstances and often for limited groups of patients been identified for people with
diabetes, being readmitted to hospital. This is a valuable resource to patients,
clinicians and academics looking to improve the process of inpatient discharge from
hospital. There is a clear need for statistically rigorous studies, to further understand
these diverse risk factors, matched to meaningful effect sizes. This is explored further
in this thesis in Chapter 5. Such research would act as the foundation for both
cohorting at risk patient populations and introducing targeted personalised
interventions, in order to improve the quality of care for provided for people with
diabetes.
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Chapter 4: Comparing Risk Factors Identified in the
Published Literature for Readmission of patients
Diabetes after Hospital Discharge with those
Considering Mortality
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4.1 Introduction
The previous chapter described a systematic review on the risk factors for
readmission, when patients with diabetes are discharged from hospital. This
represented the first systematic review of its kind [9]. Readmission represents only
one negative outcome, when patients are discharged from hospital. Readmission is a
particularly important measure, when considering hospital discharge, as it has been
persistently considered as an outcome measure for the quality of hospital care, dating
as far back as 1965 [169, 170], albeit with some debate [171]. Nevertheless,
healthcare systems, internationally, have developed deep rooted incentive and
penalty schemes for care providers, related to hospital readmission. [172-174].
Financial incentivisation has, therefore, mandated readmission rates as a priority for
both policy makers and researchers.
The PPI work, upon which this PhD is grounded, is described in Chapter 2, identified
that readmission rates are not the only important factor relevant to people with
diabetes on discharge from hospital and indeed logically other outcome measures,
such as mortality would have a very prominent importance. We know that patients in
hospital are at an increased risk of mortality if they have a comorbid diagnosis of
diabetes [55]. There is evidence that, where there is this increased risk of inpatient
mortality, this also translates to an increased risk of mortality following hospital
discharge [75, 175].
Therefore, there is a clear need to build on the first systematic review, which considers
the risk factors for readmission of patients discharged from hospital with diabetes, by
looking at risk factors for mortality for patients with diabetes discharged from hospital.
This second systematic review’s methodology was directly modelled on the
methodology used in the readmission review [9], with the author of this thesis as the
second reviewer to establish as systematic approach. This chapter, therefore, looks
to provide a direct comparison between the two systematic reviews, in order to develop
an understanding of differences between readmission and mortality outcomes, as
discussed in the research literature.
This comparison is important in establishing a foundation for data extraction and
analysis across the informatics elements of this thesis’ research, by ensuring that the
data inputted is pre-specified as equally for mortality as it is for readmission outcomes.
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The research, however, has wider implications in highlighting differences between the
research literature, considering readmission and, arguably, the more neglected
outcome of mortality. It goes without saying that reducing mortality is of enormous
interest to patients, but also to clinicians and policy makers. It is important that a
diverse panel of outcome measures are given parity to enable us to develop effective
healthcare processes and develop future meaningful risk stratification tools.
Page 59 of 155
4.2 Methods
This systematic review was developed following the same PRISMA based
methodology, as the systematic review, previously described, for readmission. This
was planned to enable direct comparison between the two studies [85]. The
methodology will not be repeated in this chapter, however the Search terms used to
identify relevant medical literature for mortality outcomes ("mortality" or "death" or
"died"). The search was performed for papers published between March 2014 to
March 2019, with a subsequent update to January 2020. Data extraction was to a pre-
defined and piloted data extraction form, modelled on that used for chapter 3 and
included as Appendix 5. Identification of papers, data extraction and data synthesis
was performed in a rigorous two-author manner. The PRISMA flowchart, shown below
in figure 4, describes the search process and resulting papers identified.
Records identified through 3 database

























Records after duplicates removed (n = 2,233)
Records excluded (n = 2,039)
Full-text articles excluded
(n =167)
[Risk of other diseases / events
with T2D = 18
Diabetes as a risk factor of other
conditions = 39
In-hospital mortality = 31
Management of diabetes = 23
Off topic = 56]




Automatic = 393 and manual = 98]
Records retained after title and abstract
screening (n = 194)
Full-text articles assessed for eligibility
(n = 194)
Figure 5: PRISMA Flow Diagram of Study Selection
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Following identification, extraction and analysis of risks factors for mortality, the author
of this thesis compared the two systematic reviews in a structured and systematic
manner. This included a quantitative comparison of studies and outcomes, as well as
a semi-quantitative evaluation of secondary measures, such as country or origin.
Finally, to ensure a comprehensive appraisal, a qualitative comparison of study quality
was performed based around the 5Cs described by Keshav (category, context,
correctness, contribution and clarity) [86]. A summarized version of the results of the
mortality systematic review are presented in section 4.3, followed by a detailed
comparison between the two studies, which represents the main focus and output of
this chapter.
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4.3 Results
4.3.1 Search results
2,724 studies were identified from the literature search, representing 2,233 studies
following removal of duplicates. Title and abstract based screening resulted in 2,039
articles being removed, which left 194 for full text assessment. Full text evaluation
resulted in 27 articles being shortlisted for the review.
Study characteristics
From the 27 articles identified, 21 were full text articles (78%) and 6 (22%) were only
in abstract form, typically from conference presentations.
The study designs noted within the review were:
Study Design Number of Papers Percentage of papers (%)
Retrospective study 15 55
Prospective study 7 26
Registry based 4 14
Post Hoc Analysis 1 5
Table 6: Study design
The distribution of studies over time is described in figure 2:
Figure 6: Publication of studies over time
3 (11%) studies were based on international datasets, 9 studies (33%) were conducted
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centre studies. The distribution of study geographies is shown in Table 7 and a
breakdown of the studies is presented in Table 8.
Study Location # studies Study Location # studies Study Location # studies
United States 3 Canada 1 Spain 1
Australia 2 China 1 Middle East 1
Brazil 2 Croatia 1
Romania &
Germany 1
Greece 2 Finland 1 USA & EU 1
Italty 2 Germany 1
Taiwan 2 Israel 1
United Kingdom 2 Latvia 1
4.3.2 Risk Factor Identification
The majority of studies analysed (17 studies, 63%) identified one 1 or more statistically
significant risk factors for mortality, following discharge from hospital with a co-morbid
diagnosis of diabetes. There were 10 studies (37%), which identified no statistically
significant risk factors. The distribution of risk factors is demonstrated in more detail in
table 9.
The follow up period, during which mortality was looked for in the studies, was highly
variable. The most common follow up period was 12 months in 7 studies (26%). The
shortest follow up period was 1 month and the longest follow up period was 9.9 years.
The extracted studies varied according to whether they considered risk in all patients
with diabetes (6 studies, 23%) or a specific sub population. Those sub populations
were defined either by the type of diabetes, or the characteristics relevant to the
inpatient stay, and are demonstrated in more detail in table 8.
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Table 7: Study characteristics
The statistically significant risk factors identified have been grouped, according to the
same categories described within the initial readmission systematic review. This was
also done alongside a grouping strategy according to whether they were identified for
all patients with diabetes, or only for a specific subpopulation. In total, there were 43
distinct risk factors were identified; these are shown in table 9.
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Risk Factors for Specific Diabetes Subpopulations Risk factors in general diabetes populations
Risk Factor Number of studies & Ref Risk Factor No. & Ref
Demographic
Age
7 [176, 177, 181, 184, 185, 188,
191, 192] Age 2 [180, 193]
Gender 1 [176] Gender 2 [180, 193]
Race 1 [176]
Socioeconomic Status
Employment status 1 [177]
Lifestyle
Leisure time activity 1 [177]
Patient medical factors
Co-morbidity 5 [176, 177, 181, 189, 191] Co-morbidity 2 [180, 193]
Malnutrition 1 [185]
Duration of diabetes 1 [184]
Severity score 4 [176, 181, 191, 192]
DKA Severity 1 [113]
Body mass index 3 [177, 181, 187]
Gait speed 1 [179]
Calf circumference 1 [179]
Angina frequency 1 [177]
Inpatient Stay Factors
Procedure 2 [177, 185]
Admission diagnosis 1 [185]
Length of stay 1 [188]
Glasgow coma score (GCS) 1 [192]
Mechanical ventilation 1 [192]
Number of organs supported 1 [192]
No. of hospitalisations 1 [184]
Which hospital admitted to 1 [176]
Medication Related
Beta blocker 1 [181]
ACEi / ARB blocker 1 [181]
Statins prior to AMI 1 [183]
No. of medications at discharge 1 [183]
Insulin initiation 1 [189]
Clopidogrel 1 [191]
Laboratory Results
Admission creatinine 2 [177, 192] Hba1c 1 [202]
Fasting glucose 1 [177]
Sodium level 1 [181]




PCO2 (on blood gas) 1 [192]
Admission haemoglobin 1 [177]
Anaemia 1 [191]
Glycaemic Status (not including Hba1c above)
Glycaemic variability 1 [198]
Mean capillary blood glucose 1 [202]
Insulin resistance 1 [202]
Table 8: Identified risk factors
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4.3.3 Study quality
The sample size of extracted studies varied between 130 participants and 843,978
participants. The mean average number of participants, per study, was 51,445 - with
a median of 1,743 participants.
All the papers used statistical tests to assess the impact of potential risk factors and
evaluate their significance. Statistical significance was set at a standard of p-value
less than 0.05. The majority of the papers, which was 11 in number (41%), used Cox
proportional hazards model. 5 papers (18%) used univariate and multivariate Cox
regression analysis, 5 papers (18%) had not defined their statistical test, 3 studies
(11%) utilised univariate and multivariate analysis, 2 papers (6%) used multivariate
analysis, 1 study (3%) used multivariate binary logistic regression and finally 1 more
study (3%) used parametric and non-parametric tests. No studies considered the
application of standardised effect size measures. There was very limited calculation
of power sizes, in advance, in order to identify the appropriate population size for the
studies
4.3.4 Comparison between Readmission & Mortality Studies
A summarized comparison between characteristics of readmission and mortality
studies is shown in Table 10, below. The differences between these studies are
elaborated further in the discussion section 4.4.
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Comparator Readmission Mortality
Study Identification
Total records identified 1562 2724
Studies accepted 82 27
Studies with statistically significant risk factors 47 16
Study Characteristics
Retrospective study design 84% 55%
Qualitative studies 1 0
Number of RCTs 2 0
Qualitative Studies 1 0
Median sample size 6603 1743
Measure of duration of follow up
Total number of countries contributing data
Number of studies from UK data 9 (11%) 2 (7%)
Number of studies from USA data 54 (66%) 3 (11%)
Proportion of studies single centre 34 (41%) 9 (33%)
Generalised population of patients with diabetes 19 (23%) 4 (15%)
Specific population of patients with diabetes 28 (77%) 23 (85%)
Studies reporting standardised effect sizes 0 0
Risk Factors Extracted (Statistically Significant)
Mean average risk factors per study 5.62 2.56
Total number of statistically significant risk factors 72 43




Patient medical 16 9
Inpatient stay 23 8
Medication 16 6
Laboratory results 7 10
Glycaemic status 0 3
Table 9: Comparison between readmission and mortality risk factors.
In addition to these quantitative differences, it is important to consider more differences
in study quality between the two groups. It is already evident that there is a substantial
difference is sample sizes, with much larger sample sizes being observed for
readmission, as compared to mortality studies. Similarly, when assessing the clarity
and contribution of each paper, it is important to note that there was a higher proportion
of abstracts within the mortality papers, as compared to the readmission papers, which
had less information about the methodological approaches performed. The mortality
articles included fewer reports of retrospective studies, compared to the readmission
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papers. This difference is important, because many of the retrospective reviews relied
on the accuracy of data inputted or collected from electronic health records. This was
highlighted as a limiting factor in a number of the papers. The increased use of
prospective study design, within the mortality group of papers, reduces the impact of
errors present within retrospectively extracted data. However, this in turn raises
concerns about how generalized the results can be, based on the specific
characteristic of prospectively recruited cohorts, which, in a number of papers, were
quite specific to particularly small subpopulations of patients.
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4.4 Discussion
Readmission and post-discharge mortality are important negative outcomes in the
context of discharge from hospitals. Clinicians, managers and policy makers are
undoubtedly motivated to reduce both outcomes. However, such a motivation is more
typically avoiding readmission, and this is associated with financial incentivisation.
There are clear differences, within the published research literature, between the two
outcome measures. Whilst the initial search identified a far greater number of articles,
considering risk factors for mortality, in comparison to risk factors for readmission,
once the filtering process had been completed, only 27 articles were remaining that
considered risk factors for mortality, in comparison to 82 articles for readmission. The
frequent use of 28 day or 30 day readmission, as the time point for including a
readmission outcome supports the potential of financial incentivisation being a driver
for increased readmission-based research, given these time periods are typically used
in compensation algorithms. Furthermore, there was a much higher proportion of
readmission based studies originating from the United States and the United Kingdom,
in comparison to mortality outcomes. Both these countries were early adopters and
prominent users of readmission as a financial incentivisation measure [203, 204].
It is unlikely that financial incentivisation alone was a core driver in this difference.
Importantly, the follow up time for patients to readmission was much shorter than the
follow up time in studies looking at mortality. This is likely to be because readmission
is a more common negative outcome than mortality, and tends to happen sooner after
the index admission. Researchers selecting a quality measure, against which to
evaluate the discharge process, are more likely to gain a richer dataset by looking at
readmission, in comparison to mortality. Furthermore, mortality data is typically
considered to be relatively low fidelity with limited accuracy of death certificates or
delays, in this information being entered into electronic health records [205, 206].
These factors may also explain why a higher proportion of papers considering
mortality, utilised prospective data collection methods, in comparison to those studies
considering readmission (45% vs 16%).
The greater use of retrospective methodologies, for the studies considering
readmission, may also explain the larger samples sizes seen in the readmission
studies (median sample size 6603 vs 1743), given the retrospective methodology
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would facilitate easier and more cost effective evaluation of a larger cohort of patients.
Similarly, the opportunity to extract large amounts of data from electronic health
records, for patients with diabetes, may, perhaps, help explain the difference in the
mean average number of statistically significant risk factors, identified per paper for
readmission, in comparison to mortality (5.62 vs 2.56 risk factors per study).
There exist considerable differences in the risk factors, identified between the two
outcome groups. Both groups had risk factors identified for all the main risk factor
categories (demographic, socioeconomic, lifestyle, patient medical, inpatient stay,
medication and laboratory groups). The mortality literature was the only literature to
identify an association between glycaemic status, beyond Hba1c, and a negative
outcome, which is important given the increasing interest on alternative measures of
glycaemic control such as time in range [207]. Importantly, however, these additional
factors were only identified in one paper.[208].
Possibly, one of the most interesting differences between the two outcome groups is
that, a larger proportion of the readmission papers (23% vs 15%) considered risk
factors for populations of patients with diabetes, in general, as compared to specific
subpopulations of patients with diabetes. This is important in planning further health
informatics work, given this precedent to cohort groupings of patients with diabetes.
There is, however, an important opportunity here, given that all the papers considering
a subpopulation of patients with diabetes, across both mortality and readmission,
consider either only one subpopulation or a close-knit grouping of subpopulations.
What is was not done was to cohort a population of patients with diabetes and then
analyse each cohort separately, in order to allow comparisons between the different
groups. This is an opportunity that is exploited later in this PhD Thesis in chapters 5,
6 & 7.
Another important element, which supports the approach adopted in this thesis, is that
across the two reviews of mortality risk factors and readmission factors, there is no
overlap in the papers extracted, suggesting that no study has previously compared
both readmission and mortality outcomes.
Together, the two systematic reviews, presented and compared here, provide an
important foundation for this thesis. They highlight both readmission and mortality as
important outcome measures, following hospital discharge, with a combined total of
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over 100 papers considering risk factors relevant to these outcomes. A particularly
valuable output is that the categorisation and risk factors, themselves, enable a degree
of pre-specification of candidate risk factors for health informatics evaluation.
There are important limitations to the comparison of the systematic reviews presented
here. The most important limitation is that there was a slight variation in the personnel
conducting the reviews. The first readmission review was conducted by the thesis’
author, with Professor Arvanitis as the second reviewer. In contrast the mortality
review was conducted by an MSc student with the thesis’ author as second reviewer.
The author of this thesis then performed the comparison presented here. It could be
argued, therefore, that the variation in project team could account for some of the
differences seen between the studies. The author of this thesis would, however,
suggest that the protocol and approach developed, in the readmission review, has
been closely followed here, supervised by the author himself, so any structural
variation is likely to be minimal. The second important limitation is in the process of
the literature search itself. The search was limited to English Language papers, over
the last 5 years and only articles published in the published research literature. It is
possible that there is content relating to mortality or readmission available in other
sources, for example the grey literature, and that this information may not be balanced
(for example, more information may be available for one outcome vs. another). It would
be difficult to identify particular grey literature sources for this rea, for whilst there is an
annual National Diabetes Inpatient Audit, this does not specifically look at readmission,
nor have there been any National Confidential Inquiries into post-discharge mortality
for diabetes. We, therefore, believe that the majority of information can be captured
from the published research literature.
Concluding Remarks
Readmission and mortality are both important outcomes, following discharge from
hospital with diabetes. There are clear differences in the maturity of the published
literature in relation to these two outcomes. Common to both, however, is that there
is a sufficient depth of literature to pre-specify candidate risk factors for subsequent
data extraction and statistical analysis. The following chapters of this thesis utilise
the information identified in the systematic reviews to further interrogate risk factors
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for both readmission and mortality, when patients with diabetes are discharged from
hospital.
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Chapter 5: Application of Standardised Effect Sizes
to Hospital Discharge Outcomes for People with
Diabetes
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5.1 Introduction
Increasing numbers of hospital inpatients have a co-existent diagnosis of diabetes
[209]. These patients are at an increased risk of both readmission [210] and mortality
[211, 212]. Chapters 3 and 4 have identified that multiple studies have been
performed, aiming to identify statistically significant risk factors for these poor
outcomes, when patients with diabetes are discharged from hospital [63, 99]. These
studies typically identify risk factors for generalised populations of inpatients with
diabetes [125, 126], or for specific cohorts of patients, who may have been admitted
for a particular condition or group of conditions [139, 144, 147]. Almost universally,
these studies report statistically significant risk factors for an individual outcomes
(either readmission or mortality) and report unstandardised effect size measures,
usually as odds ratios [117].
The use of unstandardised effect size measures, which report only on individual
outcomes for individual patient cohorts, makes effect size comparisons between
groups difficult. Comparisons between studies are additionally difficult as, unlike
clinical trials, extracted electronic health record data is rarely made available as
supplementary material to research articles, due to the risk of inadvertently
compromising anonymity of the data. Furthermore, whilst standardised effect sizes
can be calculated if both the sample size and standard deviation are given with
unstandardised effect statistics in articles, it is recognised that this information is too
often incomplete and can be a laborious process across multiple studies even if it is
available [213].
This represents a key challenge in identifying optimal targets and outcome measures
for the delivery of interventions to improve the discharge process from hospital for
patients with diabetes. In particular, attempts to create risk stratification tools for
patients with diabetes, at discharge, have only had limited success, often reporting
only moderate area under the curve (AUC) values and restricted predictive values
[124, 149].
Standardised effect size calculations allow the direct comparison between risk factors,
outcomes and cohorts. Similar to other statistical tests, there are a range of effect size
statistics available, with well over 60 reported in the literature [214]. The appropriate
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standardised effect size statistic needs to be selected as relevant to the variables in
question, with d statistics (such as Cohen’s d or) appropriate for continuous dependant
variables & categorical predictors, whilst differing tests are relevant for effect size
estimates related to categorical data (such as Phi or Cramér’s V) [215].
Effect sizes are descriptive statistics that support both clinicians and researchers to
interpret study findings. The interpretation of effect sizes can be done in isolation,
against pre-defined published levels of effect or “rules of thumb” [119]. Table 11
demonstrates published rules of thumb for Cohen’s d [216] and Phi statistics [120,
217]. However, the importance of any effect is dependent on what is being studied,
with for instance very small effect sizes being important in certain circumstances (for
example life threating situations) [218]. Effect sizes statistics are also particularly
valuable when looking to make comparisons, for example between different predictors,
cohorts or variables. It is primarily in this context that standardised effect sizes have
utility in considering risk predictors for negative clinical outcomes.
In this study, we extract data from a
large tertiary referral centre in order to
calculate standardised effect sizes for
pre-specified risk factors, across
outcome measures and across patient
cohorts. This research demonstrates
the importance of calculating
standardised effect sizes, a practice
more typical in the psychological
literature than medical literature. It further demonstrates important variation in risk at
discharge from hospital for patients with diabetes.
Effect Size d value Effect Size d value
Very small 0.01 Negligible 0.00 to <0.10
Small 0.2 Weak 0.10 to <0.20
Medium 0.5 Moderate 0.20 to <0.40
Large 0.8 Relatively strong 0.40 to < 0.60
Very large 1.2 Strong 0.60 to <0.80
Huge 2 Very strong 0.80 to <1.00
Cohen's d Phi Coefficent
Table 10 "Rules of thumb for interpreting effect sizes"
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5.2 Methods
The study adopted a retrospective evaluation of data extracted
from electronic health record (EHR) of a large tertiary referral
centre, in the West Midlands region of the United Kingdom, for all
patients discharged from University Hospitals Coventry and
Warwickshire NHS Trust with a diagnosis of diabetes, over a 3-
year period from October 2014 to October 2017. Data were
extracted for an exemplar set of 10 pre-specified risk factor
variables. These variables were selected based on both pre-
specification from the published research literature, and the ease
of which data for these variables can be extracted from inpatient
electronic health records. Ease of extraction was considered to
ensure the results are generalizable to other healthcare organisations internationally.
The selected extracted variables are listed in Table 12. Outcome variable data were
extracted for hospital readmission within 30 days and mortality within 180 days of
hospital discharge.
The diagnosis of diabetes was taken from the coding of patients at discharge and,
thus, if there was discrepancy in the diagnosis within the record, the latest diagnosis
of diabetes at discharge was used. Maternity patients were excluded from the study,
due to the differing nature of maternity care and readmission patterns. Patients
discharged within the last 6 months of the study period were not evaluated as index
patients, to ensure that all patients had a full period of 6 months follow up on the
electronic health record, in order to assess for the outcome measures of interest.
The association between risk factor variables and outcomes of interest was analysed
using Chi Squared Test for categorical variables and Student’s T Test for continuous
variables, following adequate assessment for skew and kurtosis to ensure normality.
An absolute skew value larger than 2 or an absolute kurtosis (proper) larger than 7
may be used as reference values for determining substantial non-normality [219].
A p-value of <0.05 was considered significant. Standardised size was evaluated using
Phi coefficient for categorical variables and Cohen’s D for continuous variables. The
statistical significance and effect size were evaluated for the following patient cohorts:
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all patients discharged with a diagnosis of diabetes; all emergency admissions
discharged with a diagnosis of diabetes; all emergency admissions discharged with a
diagnosis of T2DM; all emergency admissions discharged with a diagnosis of T1DM;
all elective admissions discharged with a diagnosis of diabetes; all elective admissions
discharged with a diagnosis of type 2 diabetes; all elective admissions discharged with
a diagnosis of T2DM; all patients with diabetes discharged from surgical care; all
patients with T1DM discharged from surgical care; and all patients discharged with
T2DM from surgical care.
All statistical testing was performed using Microsoft Excel 2016 [220] and IBM’s SPSS
v24 [221].
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5.3 Results
Data was extracted for 46,367 distinct patient episodes resulting in discharge from
hospital, over the study period, with a diagnosis of diabetes. Table 13 demonstrates
the number of patients in each cohort. Table 14 illustrates the statistical significance
of each risk factor in relation to readmission per patient cohort, separated into
categorical risk factor variables (evaluated with the Chi Squared Test) and continuous
variables (evaluated using student’s T Test) for readmission. Table 15, similarly,
demonstrates statistical significance testing for mortality. Table 16 illustrates the
standardised effect sizes of each risk factor related to readmission per patient cohort,
separated again into categorical risk factors (evaluated using Phi coefficient) and
continuous risk factors (evaluated using Cohen’s D). Table 17 illustrates effect sizes
in relation to mortality at 180 days.
Patient Cohort Number of
patients in sample
All patients discharged with a diagnosis of diabetes 46367
All emergency admissions discharged with a diagnosis of diabetes 20140
All elective admissions discharged with a diagnosis of diabetes 23379
All emergency admissions discharged from surgical care with diabetes 3032
All medical admissions discharged from surgical care with diabetes 14250
All surgical care discharges with type 1 diabetes 399
All surgical care discharges with type 2 diabetes 2547
All medical care discharges with type 1 diabetes 1455
All medical care discharges with type 2 diabetes 12498
Table 12 Patient cohorts and sample size
Statistically significant associations, with readmission at 30 days, were found for 46
cohort/risk factors combinations, with 61 statistically significantly associations for
mortality at 180 days. Following expectations, the effect size of most risk factors
individually on outcomes was small. However, there was significant variation in effect
size between risk factors, cohorts and outcome measures. The mean average effect
size for categorical values considering readmission (Phi Coefficient) was 0.05, with
the mean average effect size for continuous variables being (Cohen’s D) 0.22. Mean
average effect size for categorical values, considering mortality, was 0.06 (Phi
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coefficient) and for continuous variables 0.83 (Cohen’s D). Effect sizes were notably













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 84 of 155
5.4 Discussion
In this chapter, the author demonstrated that there is substantial variation in the effect
sizes, regarding risk factors related to poor outcomes at discharge from hospital for
patients with diabetes. Whilst a large number of candidate risk factors have been
identified as statistically significant, there is variation in the effect sizes between
individual risk factors. Typically, effect sizes for mortality were greater than effect sizes
for readmission, suggesting that using the risk factors described here, it may be easier
to predict risk related to mortality than readmission. This is particularly interesting,
given that readmission is most commonly used as the marker of the success of the
discharge process and a typical target for risk predication modelling and risk reduction
interventions.
There is also substantial variation in both the statistical significance and effect size of
individual risk factors between cohorts of patients with diabetes, as well as the overall
combined effect sizes between individual patient cohorts. This suggests, again, that
risk prediction may be easier for some cohorts of patients, particularly those with
T1DM & those attending for surgery. The ability, with which we are able to predict risk
from known risk factors, is important in the development and appropriateness of
developing risk prediction tools, but also in targeting interventions to those most at
need. The targeting of interventions, supported by evidence-based discussions of risk
with patients, is essential to individualised sustainable healthcare.
This part of this thesis’ research does not aim to provide a comprehensive assessment
of effect sizes for every patient cohort with diabetes at discharge from hospital, or for
every known risk factor for poor outcomes. Rather, we demonstrate the substantial
variations of standardised effect sizes between risk factors, outcomes and patient
cohorts. This, therefore, lays important foundations for future research looking to
explore individual risk factors, outcomes or cohorts in more depth, before possible
future development of rigorous risk prediction models.
The study has a number of limitations. Firstly, it is based only at a single centre, albeit
with a large patient population over a significant period of time. Secondly, we have not
attempted to control individual risk factors at this stage; this approach is, however,
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representative of the many studies identifying new risk factors and subsequently
reporting with unstandardised effect sizes.
When considering the utility of standardised effect sizes it is notable that we have used
two different effect size statistics (Cohen’s d & Phi coefficient), whilst the primary aim
of using standardised effect size statistics is to enable comparison the outputs of the
two statistical methods cannot be directly compared due to variations in the “rules of
thumb” for their interpretation. Whilst some processes to enable conversion between
effect size statistics have been published, there is no accepted approach to converting
between all effect size statistics [215].
5.5 Concluding Remarks
In this chapter, the author demonstrated the calculation of standardised effect sizes
for risk factors related to poor outcomes when patients are discharge from hospital.
Whilst individual effect sizes are often small, there is substantial variability between
different risk factors, patient cohorts and outcomes. The use of standardised effect
sizes allows the easier comparison between such groups, this in turn may facilitate the
development of better risk stratification models and risk minimisation interventions. We
hope that, as a consequence of this work, more studies will look to calculate
standardised effect sizes when considering risk factors, generating more directly
comparable results and enabling more rapid translation into changes to patient care.
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Chapter 6: Impact of Socioeconomic Geography on
Outcomes at Hospital Discharge for People with
Diabetes
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6.1 Introduction
Chapter 5 considers risk factors, related to commonly extracted variables, associating
to readmission and mortality for people with diabetes. These variables were informed
from the systematic reviews in Chapters 3 and 4. Both these reviews, however,
identified a potentially important role for socioeconomic variables related to outcomes,
following discharge from hospital. This Chapter considers such socioeconomic
variables in more detail. There are varying definitions of socioeconomic status, with
one of the earliest being by Chapin in 1928, who defined socioeconomic status as “the
position that an individual or family occupies with reference to the prevailing average
of standards of cultural possessions, effective income, material possessions, and
participation in group activity in the community” [222]. One of the key reasons for
variations, in this baseline definition, is the wide range of different academic disciplines
that consider socio-economic status as an important factor in their research.
Sociologists, psychologists, medical researchers, educational researchers and many
more all find the concept of socioeconomic status an important construct within their
own disciplines [223].
Whilst there are variations in the exact definition of socioeconomic status, there are
clear and widely reported associations between socioeconomic status and health
outcomes [224, 225]. These cross physical, mental and emotional health outcomes
[226, 227]. Naturally, for the purposes of this PhD we focus on the interactions
between socioeconomic status and physical health. However, the complex
interactions between physical, mental and emotional health should not be overlooked.
The driver of varying health outcomes, related to socioeconomic status, is felt to be
threefold.
Firstly, socioeconomic status has a direct impact on the ability of individuals to
purchase or acquire resources and treatments that promote health. This can include
factors impacting health directly, such as the ability to purchase medication [228], or
more indirect influencers such as living in environments with less pollution [229] or
more access to health promoting leisure activities [230].
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The second driver of health outcomes, in relation to socioeconomic status, can be
described as variations in the “socialization” of health influencing habits and activities
and then the continued [231], and perhaps compounding socialization of health
influencing habits and activities. This differs from the first driver in that it goes well
beyond simple purchasing power but deeper into personal preferences and cultural
habits between different groups. It is important to note that these habits can vary
across different socioeconomic groups over time and be health promoting (such as
exercise [232]) or health harming (such as smoking [233] or alcohol consumption
[234]). This second driver is perhaps the most important driver for public health and
state based interventions, as illustrated, for example, by minimal alcohol pricing [235,
236] or smoking bans [237].
The final driver is arguably the most interesting, in that it has been proposed, with good
supporting evidence, that in addition to socioeconomic status driving health outcomes,
health itself can driver socioeconomic status [238]. For example, people who are less
healthy may miss more school education or have lower income through more missed
days from work and increased difficulty acquiring a job. This driver acts directly at the
“person” level but also has an indirect influence on family members, in particular where
informal and unpaid caring elements are considered. Importantly, however, there may
also be a direct influence of one person’s health affecting their socioeconomic status
and that in turn also affecting the health & socioeconomic status of another individual
through the epigenetic phenomenon of imprinting whereby a parent’s status impacts
the genetic imprinting of their offspring [239].
These drivers are equally thought to apply to the context of diabetes, where there is a
long established literature considering the impact of socioeconomic factors on
outcomes. This association in diabetes was first reported in 1982, in relation to the
incidence of diabetes associated with geographic deprivation, prospectively analysed
in nine British Towns, with a particularly strong association noted for Type 2 diabetes
[240]. This was followed by abundant research considering impact of socioeconomic
status on the incidence of diabetes in varying demographic cohorts internationally
[241, 242]. Importantly, there has also been significant research considering the dual
impact of socioeconomic status and race on diabetes incidence [243].
Page 89 of 155
Subsequent research considered the impact of socioeconomic status on control of
diabetes, as well as the development of diabetes related complications in cohorts of
patient with both Type 1 and Type 2 diabetes [244]. Lower markers of socioeconomic
status have been associated with an increased T2DM prevalence [245], lesser
attainment of diabetes treatment goals [246] and increased mortality [247]. Certain
complications of diabetes, in particular diabetic foot disease have noted to be very
strongly associated with socioeconomic status and deprivation [248, 249].
There has been much less research considering the impact of socioeconomic status
on patient outcomes, in relation to in-hospital outcomes, for patients with diabetes. It
is conceivable that this is due to a perception that the hospital environment reduces
the impact of variations in socioeconomic status. The initial systematic reviews in
chapters 3 and 4 [9] did, however, report that a relatively small number of studies
considered the impact of socio-economic status on readmission rate, particularly for a
small subsets of patients with type 1 diabetes [144]. The performed studies focused
much more on the impact of socioeconomic status on readmission rather than the
impact of socioeconomic status on mortality. The contrast between socioeconomic
research for diabetes, in general, compared to research considering risk factors for
patients with diabetes, at hospital discharge, may reflect the data interoperability
challenges associated with matching diverse inpatient electronic health record (EHR),
primary care and socio-economic datasets at the individual patient level.
To understand the impact of socioeconomic status on health outcomes, it is necessary
to find a reliable source of socioeconomic data. Collecting information from individual
patients is laborious and prone to potential bias. This would not support the wider
ambition of this PhD of identifying risk through a health informatics approach. In the
United Kingdom, the UK Census provides a “treasure trove of information about UK
society,” with a core function to provide a “to provide a (near) comprehensive snapshot
of the UK population once a decade [250].”
In this Chapter, the author presents the first assessment of the impact of
socioeconomic status on the risk of readmission and mortality, at the point of discharge
from hospital for people with diabetes. The research approach combines electronic
health record data with geographic socioeconomic data, based on postcode sectors.
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The research utilises census data, published in the United Kingdom. In particular, the
indices of multiple deprivation that are collected.
This research is essential if we are to personalise healthcare services to meet the
needs of individual patients and appropriately design strategies to reduce the excess
readmission and mortality risks seen for patients with diabetes when discharged from
hospital.
6.2 Methods
The author performed a retrospective evaluation of data extracted from an electronic
health record (EHR) of a large tertiary referral centre in the Coventry & Warwickshire
region of the United Kingdom, for all patients discharged from with a diagnosis of
diabetes, over a 3-year period. Outcome variable data were extracted for hospital
readmission within 30 days and mortality within 180 days of hospital discharge.
The diagnosis of diabetes was taken from the coding of patients at discharge and,
thus, if there was a discrepancy in the diagnosis within the record, the latest diagnosis
of diabetes at discharge was used. Maternity patients were excluded from the study,
due to the differing nature of maternity care and readmission patterns. Patients,
discharged within the last 6 months of the study period, were not evaluated as index
patients, to ensure that all patients had a full period of 6 months follow up on the
electronic health record, in order to assess for the outcome measures of interest.
Patients were cohorted into those with a recorded diagnosis of Type 1 diabetes and
those with a diagnosis of type 2 diabetes. Patients with a postcode outside the
Coventry & Warwickshire Region were excluded, this is because there is an increased
risk that these patients may have attended UHCW for one admission, but
subsequently been readmitted to another hospital (for which we do not have data
collected). This process therefore helps ensure the accurate capture of readmission
rates to the hospital.
Socioeconomic data was extracted from the latest UK Census, performed by the Office
for National Statistics (ONS), this data was not available directly from the EHR. The
last UK Census was performed in 2011 and published in July 2012, it represents a
“detailed snapshot of the population and its characteristics, and underpin funding
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allocation to provide public services,” with a 93% coverage rate it is an unique an
invaluable resource, considering the characteristics of the UK population
Socio-economic data was extracted from the ONS Nomis Portal relating to the
following pre-specified variables; indices of multiple deprivation (the official measure
of relative deprivation in England [251]), adults in employment, ethnicity, language,
housing density, activity limitation and provision of unpaid care. Socio-economic data
was extracted and matched to patient postcodes within the EHR at postcode sector
level. The 5 digit postcode sector (eg “SW1A 2” from the full postcode “SW1A 2AA”)
represents the smallest area level within the Census dataset [252]. There are 89
postcode sectors, within the Coventry and Warwickshire region, with approximately
9000 people living in each postcode sector.
The association, between socioeconomic status and outcomes of interest, was
assessed using Student’s T Test for continuous variables, following adequate
assessment for skew and kurtosis to ensure normality. An absolute skew value larger
than 2 or an absolute kurtosis (proper), larger than 7, was used as reference value for
determining substantial non-normality [219].
A p-value of <0.05 was considered significant. Standardised effect size was evaluated
using Cohen’s D for continuous variables. This allows comparison between the
different markers of socioeconomic status, extracted from the UK Census data, and
across the different cohorts of patients assessed.
All statistical testing was performed using Microsoft Excel 2016 [220] and IBM’s SPSS
v24 [221].
6.3 Results
Data were extracted for 24107 hospital discharges with a diagnosis of diabetes
recorded, 2222 for patients with T1DM and 23365 for patients with T2DM. Twenty-
three percent (N=5,659) of emergency hospital admissions resulted in readmission
within 30 days for the generalised population of diabetes, with 30.5% (n=678) of
emergency admissions with T1DM resulting in readmission within 30 days and 21.3%
(n=4981) of emergency admissions with T2DM being readmitted within 30 days.
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Fifteen percent of patients (n=3719) died within 180 days of hospital discharge in the
generalised population of patients with diabetes, with 7.8% (n=175) of patients with
T1DM and 15% (n=3460) of patients with T2DM dying within 180 days of hospital
discharge.
Socioeconomic status was significantly associated with 1 of 19 variables for 30 days
readmission in T2DM patient cohorts compared to 9 statistically significant variables
for T1DM cohorts (p<0.05 Student’s T test). Standardised size measures were
relatively large and strongest for deprivation indices (Cohen’s D 0.29) and health
related activity impairment (Cohen’s D 0.15).
There was no statistically significant association between mortality and socioeconomic
variables in the T1DM cohort. Socioeconomic status was statistically significantly
associated with 14 of 19 socioeconomic variables, in relation to 180d mortality for the
T2DM patient cohort (p<0.05 Student’s T test). Standardised effect sizes were
relatively small, however strongest for language and activity limitation (both 0.09).
Tables 18 and 19 present the association between socioeconomic factors and
readmission at 30 days or mortality at 30 days for generalised populations of patients
with diabetes, T1DM populations and T2DM populations at discharge from hospital. A
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6.4 Discussion
There is a strong association between geographic socio-economic status and
readmission outcomes for patients with T1DM. However, there is very limited
association between socio-economic status and mortality outcomes for the T1DM
cohort. In direct contrast, socioeconomic status is strongly associated with mortality
outcomes, following hospital discharge, for patients with T2DM, whilst there is very
little association with readmission.
This is an important finding, as it will help guide and understanding of how to most
appropriately risk stratify these different patient cohorts at discharge from hospital, as
well as make suggestions as to the potential design of interventions to reduce
readmission or mortality following discharge. The results also go some way to
explaining variations in outcomes, when patients are discharged from hospital with
diabetes, as it suggests that both the geographic socioeconomic status and the type
of diabetes may be of significant relevance.
These results clearly demonstrate an association between geographic socioeconomic
status and outcomes, following hospital discharge. However, they do not provide any
information on causation. Further work is clearly needed to understand the possible
mechanisms for the findings reported here. In particular, we have not attempted to
control the populations for factors such as age, sex or diabetes control. Whilst we have
not controlled for such variables, the results remain meaningful and useful, in particular
in the development of risk stratification tools.
There are a number of both strengths and weaknesses with the study described.
Foremost, amongst the strengths is that we have used a large sample size over a
prolonged period of time (3 years). This is important as previously very few studies,
which have looked at the association between socioeconomic status and diabetes
outcomes, have utilised meaningful sample sizes [253]. We have however only
considered a single centre in the study described, albeit a large tertiary referral centre,
set within a diverse population representing a mix of affluence, ethnicity and
urbanisation. This consideration of a single centre does mean that some readmission
events may be missed, as patients may have been subsequently admitted to a
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different hospital in the Coventry & Warwickshire region (for example George Eliot
NHS Hospital in Nuneaton or South Warwickshire NHS Foundation Trust Hospital in
Warwick). However, the risk of this is likely to be low, as those admitted via ambulance
will typically be taken to the nearest hospital and patients tend to attend the same
hospital where they receive most of their care. Arguably the impact may be highest for
more affluent socioeconomic groups, who are likely to be more geographically mobile;
for instance, with greater car ownership and longer work commutes meaning they are
more likely to come within the catchments of different hospitals, during the follow-up
period of the study. This limitation does not apply to mortality on the basis that date of
deaths for patients within the electronic health record are extracted from General
Practice records before being uploaded to the UHCW NHS Hospital Trust electronic
health record. Therefore wherever patients die their death should be accurately coded
within the UHCW EHR from which data has been extracted.
The use of postcode sectors, as opposed to full postcodes, also merits discussion.
This was necessitated both by the availability of census data, provided within the ONS
datasets, and the additional need to ensure that patient identity was not inadvertently
compromised. From a research perspective, it would of course be interesting to repeat
the analysis with identifiable patient datasets and full postcodes with an individual
assessment of social-economic status. However, from a practical perspective the
benefits of such an approach would be limited. The use of full postcodes would not
allow more accurate information to be extracted from the census, as the census also
reports at a geographic level rather than an individual postcode based level.
Furthermore, the use of postcode sectors and publically available socio-economic
datasets allows ready and rapid incorporation of such data into risk stratification tools,
which could be implemented within hospital discharge processes without significant
disruption to the clinical teams, and yet provide valuable information. A more detailed
understanding could be achieved through a sociological based approach of assessing
each individual’s socioeconomic status directly at discharge from hospital, through a
survey or interview based approach. Such an individual assessment of socio-
economic status, at discharge, would of course be rather laborious and could not be
practically incorporated into a risk stratification tool capable of delivering point-of-care
information to clinicians, when discharging patients with diabetes from hospital.
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There are other limitations in considering the use of census based research. The first
of these is that the last census was performed in 2011, making it now 9 years old.
Whilst there has been relatively little geographic change in the population of the
Coventry & Warwickshire region, there has been significant gentrification of the city
centre area, and rapid increases in student populations in other areas. It is
conceivable, therefore, that the socio-economic status of some postcode sectors may
have changed since the census was completed and therefore not be representative of
the current population. The next UK Census is not planned until 2021 [254], with the
publication of census results typically taking a further 12 months. Given there is no
other reliable source of geographic socioeconomic based information, there is little
alternative option but to use existing census data, the vast majority of which is likely
to be representative of the patient population.
This research only considered the post-discharge outcomes of patients with type 1
and type 2 diabetes. An important cohort that was not considered are pregnant ladies
with a diagnosis of either type 1, type 2 or gestational diabetes being discharged
following delivery. Pregnant ladies with a diagnosis of diabetes are counselled to
deliver in hospital and this is essential for those on insulin replacement. The post-
discharge outcomes for this cohort of patients would perhaps need to be extended
beyond readmission or mortality, in order to consider both important maternal and
paediatric outcomes. Understanding the socio-economic impact of socioeconomic
status on diabetes control, delivery and post-delivery outcomes is particularly
important given the potential to have a direct impact on both the mother and the future
lifespan of the recently born child. This builds on the increasing evidence around the
impact of the maternal uterine environment on future diabetes and obesity risk in the
offspring [255]. There is potential, therefore, that this could act as a mechanism of
compounding socio-economic driven health inequality across generations and should
therefore be an important target for future research. Indeed, we are currently
developing a research collaboration between University Hospitals Coventry &
Warwickshire NHS Trust & The Institute of Digital Healthcare that assesses post
discharge factors relating the maternal mental health outcomes. Based on the results
discussed in this chapter, the author would suggest that an inclusion of socio-
economic factors should be incorporated within the research approach.
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6.5 Concluding Remarks
In summary, we present here the first large scale assessment of the impact of
geographical socio-economic status, collected from publically available data sources
on outcomes for cohorts of patients, discharged from hospital with diabetes. We
demonstrate clear associations between socio-economic status and readmission for
patients with T1DM and socioeconomic status and mortality for patients with T2DM.
These findings can, and we believe should be readily incorporated into risks
stratification tools applied at the point of discharge and thus supported evidence based
individualised care for patients leaving hospital with diabetes. An important element,
in the relationship between socioeconomic status and healthcare outcomes, is felt to
be the impact of socioeconomic status on glycaemic control (or Hba1c). The impact of
glycaemic control and discharge outcomes for patients with diabetes in considered in
more detail in the next chapter.
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Chapter 7: Association between glycosylated
haemoglobin and patient outcomes
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7.1 Introduction
Chapter 1 highlighted the underlying nature of diabetes as a condition of impaired
glycaemic control [22]. Therefore, one of the central features of diabetes care aims to
return glycaemic control into a physiological range through diet, oral medications or
injectable medications [25, 30]. Glycaemic control is typically measured through either
fingerpick blood sugar readings or in a laboratory blood test, termed glycosylated
haemoglobin levels (Hba1c) [256]. Fingerprick blood sugar readings provide an
immediate reading of the blood sugar level, at that point in time. Finger prick blood
tests are typically taken on a hand-held device, either the patient’s own or a healthcare
organisation’s. The glycosylated haemoglobin value (Hba1c) reports the amount of
glucose bound to haemoglobin molecules, and represents an average of blood sugar
control over the preceding 6 weeks prior to the test being taken [256]. Hba1c values
are typically collected by a venous blood sample that is sent to a processing laboratory
(although near-patient systems do exist [257]) and thus almost all such values are
uploaded to electronic health record systems (unlike many finger-prick blood sugar
samples).
There are not “normal values” for Hba1c in patients with diabetes, meaning there is no
set range of Hba1c values we expect all patients to fall within if they are well controlled;
rather these have to be individualised to each patient. The Hba1c value, however, can
be used in both the diagnosis of T2DM and monitoring of all types diabetes (although
less useful in monitoring GDM). An Hba1c of 48mmol/mol is deemed diagnostic of
T2DM, whilst an Hba1c between 42 and 47 mmol/mol is diagnostic of impaired glucose
regulation or a “prediabetes” state [258]. When monitoring control of diabetes using
Hba1c it is typically the change in Hba1c value over time that is most useful rather
than an individual Hba1c value. NICE generally recommend an Hba1c level target of
48 mmol/mol in treatment of T2DM, however, stress that this target must be
personalised and should be relaxed to 53 mmol/mol where there is a risk of
hypoglycaemia. Importantly, NICE recommend escalation of medication control where
the Hba1c is in excess of 58mmol/mol [25].
There is good evidence that maintaining glycaemic levels within physiological levels
(i.e. below the 48 mmol/mol diagnostic threshold described above) can reduce or
minimise the risk of diabetic complications in the long term (months-years), both for
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patients with T1DM and T1DM [32, 33]. Shorter-term blood sugar control also can
have a significant impact on health outcomes, with significantly higher or lower
readings resulting in significant morbidity, mortality and healthcare utilisation. Low
blood sugars (below 4.0 mmol/L) cause the condition of hypoglycaemia, which can
result in changes to conscious levels, seizures or even death [259]. Higher blood sugar
values (above 11.0 mmol/L) can cause complications (such as thrombosis) through
increased blood viscosity but, more worryingly, can also cause patients to develop
diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic states (HHS). DKA can
be defined as “an acute metabolic emergency occurring in individuals with absolute or
relative insulin deficiency and is typically characterised by hyperglycaemia,
ketonaemia and acidosis [260].” HHS, in contrast, is characterised by a high
osmolality, high blood glucose level and severe dehydration [261]. Both DKA and HHS
are associated with significant morbidity and mortality, and almost universally require
hospital admission for intravenous insulin infusions [262, 263]. It is important to note
that inter-current illnesses (such as ischaemic cardiac events, infection and trauma)
or iatrogenic insults (such as surgery and chemo/radiotherapy) can generate a stress
response within the body, resulting in excess cortisol generation and subsequent
elevations in blood sugar readings. In contrast, patients who are on hypoglycaemic
medications (including insulins and gliclazide tablets) may be at risk of hypoglycaemia,
if they are unable to eat through nausea/vomiting or loss of appetite for other reasons
[264].
Therefore, managing glycaemic control, in the context of inter-current illness and
diabetes, is a relatively complex process. In particular, there has been significant
research considering the optimal glycaemic for patients who are inpatients within
hospital settings. There is a need to balance the risks of overly tight glycaemic control
that risks hypoglycaemia versus the risks of thrombosis, DKA and HHS that can occur
with higher blood sugar values. It has been identified that glycaemic control can impact
on both survival and length of stay for people with diabetes, admitted to hospital [265].
Hyperglycaemia has clearly been associated with adverse patient outcomes across a
number of studies [266, 267]. However, interventions that have aimed to correct blood
sugars into normal ranges have either not improved outcomes [268, 269] or, in certain
circumstances, lead to worsening outcomes [269]. Randomised controlled trials have
suggested that hypoglycaemia is the primary driver of worsening patient outcomes,
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associated with overly intense inpatient blood sugar control [270]. Therefore, the
overall consensus and guideline driven position for inpatient glycaemic control is that,
in general, inpatient populations a moderate, rather than overly tight control is
advisable to optimise patient outcomes, including length of stay and readmission risk
[271].
However, when considering the impact of glycaemic control on the discharge process
from hospital, and associated risks of readmission or mortality, there has been much
less research. Two articles consider the impact of glycaemic control, in general, on
readmission; one of which focuses on the importance of the “most extreme blood
sugar value” during inpatient admission and the second article considers the impact
of glycaemic variability. Both articles therefore considered relatively specific markers
of inpatient glycaemic control and both were restricted to specific subsets of hospital
inpatients with diabetes [144, 148]. Importantly, however, there has been considerably
more research looking at the impact of inpatient hypoglycaemia on readmission
patterns for patients discharge from hospital with diabetes, with [129, 135, 136, 142].
These studies all considered generalised populations of people with diabetes admitted
to hospital, rather than specific subsets of patients. It is likely that this focus, on
hypoglycaemia and readmission patterns, is driven by an awareness of
hypoglycaemia, as a major driver of hospital admission, and therefore cost in diabetes
management. Thus, it is highly relevant to the previously discussed financial penalties
associated with hospital readmission described in chapter 3 and 4. Remarkably, there
is even less research considering the impact of glycaemic control on mortality
outcomes following hospital discharge, with no relevant articles identified during the
systematic review discussed in chapter 4.
This chapter looks to perform the first evaluation of the impact of glycaemic control on
discharge outcomes of mortality and readmission, when patients with diabetes are
discharged from hospital. It focuses on both the value of glycosylated haemoglobin
and how soon monitoring is performed after discharge. The use of Hba1c is selected
due to its ready availability in electronic health record systems, therefore facilitating an
informatics based approach both in this research, but also when considering wider
dissemination and adoption of this work in other settings.
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7.2 Methods
The work, discussed in this chapter, adopted a similar retrospective evaluation of the
EHR data extracted from University Hospitals Coventry and Warwickshire NHS Trust
for patients discharged with a diagnosis of diabetes, over a 3-year period. Only adult
patients with Type 1 or Type 2 diabetes were included. Patients with gestational
diabetes were excluded from the research. This is particularly important for the work
reported in this chapter, because Hba1c values vary significantly during pregnancy,
with no clear normal ranges established [272]. Indeed, the National Institute of Health
& Clinical Excellence do not recommend Hba1c measurement during pregnancy [273].
All Hba1c values for patients in the Coventry & Warwickshire region (including those
performed in the community setting) are analysed at the hospital laboratory and
included within the electronic health record. Patients performing Hba1c measurements
on home devices were not included, however these are exceptionally rare indeed.
Hba1c values were extracted for all patients discharged with diabetes, as above.
Patients from outside the region may have had Hba1c values calculated at other
hospital laboratories and whose readings would not appear on UHCW’s Electronic
Health Record. Therefore, patients who had postcode sectors outside of the Coventry
& Warwickshire region were also excluded from the study. Extraction of data was
supported by a biochemistry and Performance and Programme Management Office
analyst.
The outcomes of interest explored through the systematic reviews in chapter 3 and 4
were readmission within 30 days and mortality within 365 days. Associations with
these outcomes were calculated both for Hba1c tests, performed during the index
admission period, and separately for Hba1c tests performed following discharge from
hospital. The longer period used for considering mortality (chapters 5 and 6 of this
thesis have considered mortality within 180 days) is based on the nature of Hba1c as
a longer-term measure of diabetes control and therefore a longer outcome measure
was felt appropriate. Associations were investigated for generalised populations of
patients with diabetes and subpopulations diagnosed with both T1DM and T2DM. In
addition to exploring associations between the Hba1c value and the above variables,
supplementary analysis was performed to look for any association between the time
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delay (in days) between discharge from hospital, for patients with diabetes, and the
checking of an Hba1c value.
The association between Hba1c absolute values and frequency of Hba1c monitoring
was analysed using Student’s T Test, following adequate assessment for skew and
kurtosis, in order to ensure normality. An absolute skew value larger than 2 or an
absolute kurtosis value (proper) larger than 7 may be used as reference for
determining substantial non-normality [219]. A p-value of <0.05 was considered
significant. Standardised size was evaluated using Cohen’s D for pre-specified patient
cohorts of patients with Type 1 Diabetes and Patients with Type 2 diabetes. The “rules
of thumb” established for interpreting Cohen’s D values, in Chapter 5, continue to be
appropriate for this chapter.
All statistical testing was performed using Microsoft Excel 2016 [220] and IBM’s SPSS
v24 [221].
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7.3 Results
Hba1c during admission
There were 399 patients meeting the inclusion criteria described above, who had a
Hba1c sample analysed and recorded in the electronic health record system, during
their hospital admission prior to discharge. 52 of these patients were readmitted within
30 days and 63 died within 365 days. The mean average Hba1c value of this cohort
overall was 73 mmol/mol.
Hba1c during admission – readmission (Table 20)
The mean average Hba1c during admission for patients who were not readmitted
within 30 days was 74.6 mmol/mol, compared to 65.6 mmol/mol for patients readmitted
within 30 days of discharge (p=0.006, Cohen’s D 0.33).
Average Hba1c during admission n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 309 74.58 1.10 1.29
Readmitted within 30 days 52 65.62 1.78 3.98
P-value 0.0058
Cohen's D 0.33
Table 19: Association of Hba1c during admission with readmission (generalised population of patients with diabetes)
Hba1c during admission – mortality (Table 21)
The mean average Hba1c assessed during admission for patients who survived 365
days was 69.1 mmol/mol and the mean average Hba1c for patients who died within
365 days was 64.1 mmol/mol. (p=0.1, Cohen’s D N/A).
Average Hba1c during admission n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 305 69.05 0.99 0.75
Died within 365 days 56 64.11 2.19 6.37
P-value 0.10
Cohen's D 0.21
Table 20: Association of Hba1c during admission with mortality (generalised population of patients with diabetes)
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Hba1c post discharge
There were 3403 patients who had an Hba1c recorded in the electronic health record
system following discharge from hospital with a diagnosis of diabetes. There were
3138 patients who had an Hba1c within a year of hospital discharge. For patients who
had an Hba1c assessed within a year of hospital discharge the mean average Hba1c
was 59.9 mmol/mol, with an average time until Hba1c assessment of 110 days.
Hba1c post discharge readmission
When considering absolute Hba1c values and readmission for generalised
populations of patients with diabetes (n=3403), the average Hba1c value of those
not readmitted to hospital within 30 days was 60.4 mmol/mol, whereas the
average Hba1c of those readmitted to hospital was 57.8 mmol/mol (p=0.008,
Cohen’s D 0.28) (Table 22).
Average Hba1c post-discharge (All) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 2618 60.39 1.50 3.60
Readmitted within 30 days 520 57.82 1.75 4.15
P-value 0.0088
Cohen's D 0.28
Table 21: Association of Hba1c post-discharge with readmission (generalised population of patients with diabetes)
The average number of days to Hba1c testing, for those discharged from hospital
and not readmitted, was 115.2, whereas the average number of days until testing
for those discharged and then readmitted was 83.1 days. (p<0.001, Cohen’s D
0.39) (Table 23).
Average time to hba1c post-discharge (All) N Average No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 2618 115.23 0.80 -0.18
No. of days test , readmission within 30d 520 83.05 1.01 0.34
P-value 0.00006
Cohen's D 0.39
Table 22: Association between readmission and time to testing Hba1c (generalised population of people with diabetes)
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For patients with type 1 diabetes, the average Hba1c for those not readmitted
was 74.4 mmmol/mol, whereas the average Hba1c for those readmitted was 63.6
mmol/mol (p=0.0077, Cohen’s D 0.44) (Table 24).
Average Hba1c post-discharge (T1DM) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 281 74.37 1.39 4.13
Readmitted within 30 days 42 63.64 0.86 0.35
P-value 0.0077
Cohen's D 0.44
Table 23: Association of Hba1c post-discharge with readmission (T1DM population)
The average number of days, between hospital discharge and the Hba1c being
tested, was 109.4 for those readmitted and 114.9 for those not readmitted
(p=0.72, Cohen’s D N/A) (Table 25).
Average time to hba1c post-discharge (T1DM) N Average No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 281 109.46 0.89 -0.21
No. of days to test, readmission within 30d 42 114.86 0.76 -0.54
P-value 0.72
Cohen's D N/A
Table 24: Association between readmission and time to testing Hba1c (T1DM)
For patients with type 2 diabetes, the average Hba1c, for those not readmitted
was 58.8 mmol/mol, whereas the average Hba1c, for those readmitted was 57.5
mmol/mol (p=0.19, Cohen’s D N/A) (Table 26).
Average Hba1c post-discharge (T2DM) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 2246 58.83 1.45 2.59
Readmitted within 30 days 459 57.50 1.88 4.95
P-value 0.19
Cohen's D N/A
Table 25: Association of Hba1c post-discharge with readmission (T2DM population)
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The average number of days, between discharge and Hba1c being tested for
those not readmitted, was 113.5 days, compared to 95.2 days for those
readmitted (p<0.001, Cohen’s D 0.33) (Table 27).
Average time to hba1c post-discharge (T2DM) n No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 2246 113.50 0.80 -0.23
No. of days to test, readmission within 30d 459 95.23 1.05 0.50
P-value 0.00002
Cohen's D 0.33
Table 26: Association between readmission and time to testing Hba1c (T2DM)
Hba1c post discharge mortality
The average Hba1c for the generalised population of patients with diabetes, who were
discharged and survived for over one year, was 60.2 mmol/mol, whereas the average
Hba1c for those with mortality within 1 year was 56.7 mmol/mol (p=0.007, Cohen’s D
0.18) (Table 28).
Average Hba1c post-discharge (All) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 2924 60.206 1.54 3.57
Died within 365 days 214 56.73 1.28 1.97
P-value 0.0074
Cohen's D 0.18
Table 27: Association of Hba1c post-discharge with mortality (generalised population of patients with diabetes
The mean average time to Hba1c testing, for those who survived over a year, was 112
days, whereas the mean average time to testing, for those with mortality within 1 year,
was 83 days (p<0.001, Cohen’s D 0.37) (Table 29).
Average time to hba1c post-discharge n No. of days Skew Kurtosis
No. of days to test, survived 365 days 2924 112.19 0.81 -0.21
No. of days to test, died within 365 days 214 83.33 1.17 0.93
P-value <0.0001
Cohen's D 0.36
Table 28: Association between mortality and time to testing Hba1c (generalised population of people with diabetes)
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For patients with type 1 diabetes, the average Hba1c, for those who survived to
365 days post discharge, was 73.2 mmmol/mol, whereas the average Hba1c, for
those readmitted, was 59.4 mmol/mol (p<0.001, Cohen’s D 0.78) (Table 30).
Average Hba1c post-discharge (T1DM) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 308 73.20 1.27 3.58
Died within 365 days 15 59.41 -0.26 -1.57
P-value 0.00023
Cohen's D 0.78
Table 29: Association of Hba1c post-discharge with mortality (T1DM population)
The average number of days, between hospital discharge and the Hba1c being
tested, was 110.8 for those readmitted and 98.5 for those not readmitted (p=0.59,
Cohen’s D N/A) (Table 31).
Average time to hba1c post-discharge (T1DM) n No. of days Skew Kurtosis
No. of days to test, survived 365 days 308 110.89 0.87 -0.26
No. of days to test, died within 365 days 15 98.47 0.73 -0.70
P-value 0.59
Cohen's D N/A
Table 30: Association between mortality and time to testing Hba1c (T1DM)
For patients with type 2 diabetes, the average Hba1c, for those who survived 365
days post discharge, was 58.3, whereas the average Hba1c for those who died
within 365 days was 54.2 (p=0.07, Cohen’s D N/A) (Table 32).
Average Hba1c post-discharge (T2DM) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 2513 58.30 1.54 3.08
Died within 365 days 192 54.18 1.31 2.01
P-value 0.07
Cohen's D N/A
Table 31: Association of Hba1c post-discharge with mortality (T2DM population)
Page 110 of 155
The average number of days between discharge and Hba1c being tested, for
those not readmitted, was 113.5 days, compared to 96.119 days for those
readmitted (p0>0.001) Cohen’s D 0.21)(Table 33).
Average time to hba1c post-discharge (T2DM) n No. of days Skew Kurtosis
No. of days to test, survived 365 days 2513 113.53 0.80 -0.18
No. of days to test, died within 365 days 192 96.1 1.01 0.34
P-value <0.0001
Cohen's D 0.21
Table 32: Association between mortality and time to testing Hba1c (T2DM)
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7.4 Discussion
The measurement of Hba1c, in patients with diabetes, has been a mainstay of
monitoring disease and the long-term, future microvascular and microvascular risk
since the Diabetes control and complications trial (DCCT) and UK prospective
diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes
(UKPDS) published their results [32, 35]. In both these studies, increased Hba1c
values are associated with higher levels of adverse outcomes within the patient
populations. In this chapter, a first evaluation of the association, between glycaemic
control on discharge outcomes of mortality and readmission when patients with
diabetes are discharged from hospital, is presented.
The results demonstrated no statistically significant associations between the Hba1c
values, recorded during the inpatient stay, for both readmission and mortality
outcomes. It is important to note that the population size was relatively small (361
patients) for each and may, thus, contribute towards the results not reaching
significance. This small population size is notable, in that it potentially reflects a large
proportion of patients with diabetes attending hospital, but not having their Hba1c
assessed during the admission period. This does not necessarily mean that clinical
teams were not conscious of the Hba1c measure, when seeing these patients, but
they may note the most recent Hba1c, previously collected in the community setting.
Additionally, the Hba1c values typically take the laboratory, at UHCW, 24 hours to
process; therefore, this delay may mean for short admission patients clinical teams
feel there is less need to request an Hba1c value.
However, statistically significant associations were noted in relation to Hba1c values
following discharge from hospital. The Hba1c value is statistically significantly
associated with 30-day readmission and 365-day mortality, in generalised populations
of patients with diabetes. The Hba1c is statistically significantly associated with
readmission and mortality for T1DM cohorts, but not this was not seen for T2DM
cohorts. Importantly, for both the generalised population of patients with diabetes and
the T1DM cohorts, it was a higher Hba1c that was associated with lower rates of
mortality and readmission. This may seem counterintuitive; however, similar patterns
were seen in inpatient studies, based on finger-prick based glucose readings. In these
studies, higher blood sugar readings were protective [274]. This was explained by the
Page 112 of 155
high risks of negative outcomes associated with hypoglycaemia, resulting from overly
tight glycaemic control. It is likely that similar patterns may be being observed here,
with hypoglycaemia already known to be a major driver of hospital readmission [275]
and mortality [276]. It is possible that T2DM patients, who are on insulin or gliclazide
and T1DM (who are all on insulin) are the drivers of the results observed here, for both
the generalised population of patients with diabetes and T1DM cohort. The high
number of T2DM patients, who are not on hypoglycaemia inducing medications, may
explain the lack of significance in this subpopulation. The medications patients are on
is not extractable from the electronic patient record system used at UHCW NHS Trust
and the source of data for this research study. However, this is potentially an important
observation and focus of future work.
The time, between discharge and the next testing of Hba1c values, was statistically
significantly associated with both readmission and mortality, for generalised
populations of patients with diabetes. The time, between discharge and testing, was
not significantly associated with mortality or readmission for patients with T1DM;
however, it was significantly associated with patients with T2DM. The pattern for the
generalised diabetes cohort and T2DM cohort follows what would be anticipated, with
negative outcomes associated with a shorter period to Hba1c measurement. This
likely represents more frequent contact with medical team for patients with diabetes,
who are more likely to experience negative outcomes, and these medical teams
requesting Hba1c more frequently. The lack of statistically significant association for
patients with T1DM may be explained either by the smaller sample size, or perhaps,
more likely, by the more frequent contact these populations have with medical teams
as a routine part of their care, regardless of their underlying risks. Indeed, nearly all
T1DM are seen in secondary care hospital clinics, as opposed to T2DM cohorts, who
are managed in the community and, although meant to have an at least annual nurse
review with Hba1c, they have significantly less contact with medical teams.
This research work, presented in this chapter, has a number of limitations. There is
the potential for missing values and missing data. The number of Hba1c tests,
performed during the inpatient admission period, is perhaps lower than expected.
However, the extraction process was supported by a Biochemistry Analyst at UHCW
and, therefore, likely reflects a full and complete dataset, as contained within the
clinical system. Any informatics based project risks issues with data availability and
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missing values and it would be important to repeat this research at other centres, in
order to look for differences in the outcomes generated.
Secondly, Hba1c values themselves can, to some extent, be unreliable, primarily
influenced by factors affecting the lifespan of a patient’s erythrocytes [277]. Whilst, for
the vast majority of patients being discharged from hospital, they are likely to represent
a good marker of recent glycaemic control, in some circumstances they can be
misleading. Reasons for non-representative Hba1c values can include; blood
transfusions [278], pregnancy [272], sickle cell disease [279], medications [280] and
dialysis [281]. The most important of these perhaps being the impact of blood
transfusions in patients discharged following surgery, trauma or gastrointestinal
bleeding, where large volumes of blood may have been transfused.
This thesis chapter differs from previous chapters in being more exploratory in nature.
Whilst the other chapters suggest factors that could readily be incorporated into risk
prediction for patients leaving hospital with diabetes, the influence of Hba1c is less
clear. Indeed, much of the data that this chapter focuses on considers risk factors
following discharge; unlike previous chapters that focus on risk factors that are
identifiable during the hospital admission period. This work is nevertheless important
in demonstrating that biochemistry data may have an important role in understanding
risk for patients with diabetes. This is also highly relevant as new technologies may
allow earlier identification of patterns, which have been suggested by the Hba1c
results collected here. Hba1c retrospectively looks at glucose patterns over the
previous 6-week period, acting as an average effect rather than simple “point-in-time”
blood sugar readings, which are entirely dependent on when the blood sugar reading
is actually performed (in hospital, for example, the majority of fingerpick testing may
be done around acute decompensations or surgical interventions, during the inpatient
procedure, thus giving a non-representative summary of the overall blood sugar
profile. We are, however, now able to gain better understanding of average blood
sugar readings through continuous blood sugar monitoring systems (CGM) [282] or
interstitial fluid blood sugar monitoring systems, such as the Freestyle Libre [283].
Data from these systems are not widely available, in relation to inpatient care and the
immediate post discharge period. However, the research presented here suggests that
such information may be of significant importance, in better understanding the risks
when patients with diabetes are discharged from hospital.
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Finally, this chapter stresses that the hospital discharge process is a continuum, not
just a point in time, with Hba1c values stretching across that continuum. This is a
particularly important observation, as this was a feature stressed during the patient
public involvement work, at the start of this PhD thesis, and something that clinicians
often forget. The discussion chapter describes, in more detail, how this thesis can form
the basis of risk prediction modelling, at the point of discharge from hospital, and a
challenge will be considering how prediction algorithms can be responsive to both data
collected during the hospital admission itself and the post discharge period.
7.5 Concluding Remarks
Glycaemic control is currently the main indicator of effective diabetes management;
typically, this is assessed through Hba1c values. This chapter creates new knowledge
in demonstrating the association between glycaemic control, in the post discharge
period, and negative outcomes of readmission and mortality both for generalised and
specific subpopulations of diabetes. Importantly, this research extends current
understanding from glycaemic control in the inpatient setting, in that low Hba1c’s
measurements may be associated with worse outcomes following hospital discharge,
particularly for cohorts of patients with T1DM. This research represents an exploratory
chapter identifying the need for further research to characterise the “peri-discharge”
period from a glycaemic perspective. Newer technologies may enable a more detailed
understanding of how glycaemic control varies around the time of hospital discharge
and its subsequent influence on patient outcomes and thus could form the foundation
of important future grant applications, publications and high-impact research.
Page 115 of 155
Chapter 8: Discussion & Conclusion
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8.1 Introduction
Diabetes is known to be a data-rich pathology, with a wealth of readily extractable data
available on clinical electronic patient record systems [6]. Diabetes also represents a
significant challenge to modern healthcare services, given the increasing prevalence
of diabetes as a disease [284], and the increasing complexity/cost of managing both
diabetes itself and subsequent complications [285]. Whilst significant research has
been conducted to guide understanding of diabetes care in both the community setting
and in the hospital inpatient setting, much less research has considered that key
transition point from hospital to community care, when a patient with diabetes is
discharged from hospital [9]. The patient and public involvement (PPI) work, described
at the start of this thesis, demonstrated very clearly that this transition point is
considered to be vitally important to people with diabetes and their carers. However,
the transition is often neglected by the clinical teams who care for such patients.
Clinicians are more likely to see hospital discharge as a point-in-time, the end-point of
hospital admission, whereas patients, and their carers, see this as a process in itself,
with risks and quality measures associated to the discharge processes rather than to
the admissions process as a whole. The increased availability of data from electronic
patient record systems, for the first time, allows us to better delineate and understand
that discharge process and factors associated with it.
This thesis is based around better understanding the association between potential
risk factors and the negative outcomes of hospital readmission and mortality for
patients with diabetes. The research is founded within the existing research literature,
by comparing and contrasting two comprehensive literature reviews. The research
then goes on to generate new knowledge directly from extracted electronic patient
record data that may be used to support the development of better understanding and
processes around hospital discharge, as well as forming the starting point for a number
of new and exciting research proposals that span across both medical and data
science based research.
This discussion chapter explores the results of the research described so far in this
thesis in more detail, whilst highlighting the learning and new knowledge generated as
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a consequence. The strengths and weaknesses of the approach are considered in
detail, alongside a consideration of potential next steps for this research.
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8.2 Results Summary
The initial systematic in Chapter 3 review identified 82 studies, which met the inclusion
criteria for papers considering risk factors for readmission when patients with diabetes
are discharged from hospital. Only 47 of these studies identified statistically significant
risk factors associated with hospital readmission. When combining these studies,
there are 72 distinct risk factors identified, either for generalised populations of people
with diabetes or for specific cohorts of people with diabetes. The risk factors could be
broadly grouped into the following categories: demographics, socioeconomic status,
lifestyle, patient medical factors, inpatient stay factors, medication related or laboratory
results. There was, however, a strong bias towards studies from the United States,
which were typically based on retrospective data collected from US healthcare models,
incorporating the US approach to hospital discharge and diabetes care. It is important
to note that these approaches differ significantly from care models in the United
Kingdom and other areas of Europe.
The systematic review for readmission risk was then compared with a systematic
review considering risk factors associated with mortality, when patients with diabetes
are discharged from hospital in Chapter 4. There has been much less research
considering this area, with only 27 articles identified, of which 17 identified statistically
significant. These risk factors could be grouped into similar categories (demographics,
socioeconomic status, lifestyle, patient medical factors, inpatient stay factors,
medication related or laboratory results) and again were based either on generalised
populations of people with diabetes or specific cohort (for example, patients with type
1 diabetes). Importantly, in this systematic review there was an additional category
identified, which was glycaemic control. This was different to the laboratory blood tests
identified in the readmission systematic review.
These two systematic reviews in Chapter 3 & 4 identified an existing body of research
that considers factors associated with negative outcomes, when patients with diabetes
are discharged from hospital. This provided a solid foundation for the subsequent
research performed, including the precedence and potential value of analysing both
generalised populations of people with diabetes and more specific cohorts of diabetes
(most commonly T1DM and T2DM). What was noticed, in the systematic reviews, was
that typically there was significant underlying variation in the patient populations
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described (both in the generalised patient populations and specific patient
populations), alongside with significant variation in the definition of readmission or
mortality and use of non-standardised effect size statistical tools. The latter precludes
a meaningful quantitative comparison or meta-analysis of the effect sizes described,
in order to create a “hierarchy” of risk factors, or to assess the consistency across
studies identifying the same risk factors. This is compounded by the use of
anonymised, retrospectively collected data that, due to ethical approvals and the risk
of inadvertent patient identification, are not included in the appendices of the published
papers. This means that it would be very difficult to use the existing research literature,
as reported in these systematic reviews, to form the basis of a future, properly pre-
specified risk prediction model.
The subsequent PhD chapter, Chapter 5, then, outlines and demonstrates the
calculation of standardised effect size measures for risk factors, associated with
readmission and mortality for patients with diabetes. The research is based on data
that were extracted from the electronic health record of a major tertiary referral centre,
over a 3-year period, for all patients discharged from hospital with a concurrent
diagnosis of diabetes mellitus. Data were analysed for an exemplar set of 10 pre-
specified risk factor variables. These variables were selected based on both pre-
specification from the published research literature reviews, described earlier, and the
ease of which data for these variables can be extracted from inpatient electronic health
records. Ease of extraction was considered to ensure the results are generalizable to
other healthcare organisations, internationally. The chapter successfully
demonstrated the use of Cohen’s-D and Phi standardised effect size statistics. Effect
sizes were noted to be larger for mortality compared to readmission, as well as for
being larger for surgical and Type 1 diabetes cohorts of patients.
Whilst Chapter 5 explored risk factors that featured in a large number of the articles
identified within the initial systematic review, Chapter 6 considers the impact of socio-
economic geography, in more detail. The work discussed there quite significantly
extends the small amount of literature on the subject, in relation to discharge of people
from hospital with a diagnosis of diabetes. Chapter 6 identified that socioeconomic
status was statistically significantly associated with 14 of 19 socioeconomic variables
in relation to 180 day mortality for the T2DM patient cohort, with no statistically
significant association between mortality and socioeconomic variables in the T1DM
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cohort. Socioeconomic status was significantly associated with 1 of 19 variables for
28 day readmission in T2DM patient cohorts compared to 9 statistically significant
variables for T1DM cohorts. Effect sizes were strongest for deprivation indices
(Cohen’s D 0.29) and health related activity impairment (0.15). The work, in effect,
suggests that there is an association between the socioeconomic geography of where
you live and your risk of mortality, following hospital discharge if you have T2DM.
Whereas, if you have T1DM, the association is between the socioeconomic geography
of where you live and your risk of readmission.
The final experimental chapter (Chapter 7) is more exploratory, considering the impact
of glycated haemoglobin on the outcomes of interest. It works towards the
aforementioned discussion of the discharge process as a continuum, with the impact
of Hba1c both before and after discharge considered. The chapter identifies that lower
Hba1c values, following discharge from hospital, are significantly associated with
increased risk of readmission, as is a shorter duration until testing, with similar patterns
observed for mortality. The findings were particularly prominent for cohorts of patients
with T1DM. This chapter paves the way for further research, considering the impact
on glycaemic control on discharge outcomes for patients leaving hospital with
diabetes. Such research will become more feasible once newer technologies (such as
continuous glucose monitoring or closed loop systems) are more fully adopted into
both inpatient and community care.
An important element of this PhD is that the experimental chapters all use
standardised effect size measures, allowing ready comparison between the different
variables of interest (both dependent and outcome variables). This is significantly
different to any of the articles identified during the systematic reviews. It is, therefore,
an important source of new knowledge generated from this thesis. The collated effect
size outcome measures are presented below. Only those associations found to be
statistically significant are included. It is important to distinguish between the
categorical Phi effect size measures and continuous Cohen’s D effect size measures,
as these, unfortunately, cannot be compared directly. They cannot be directly
compared due to variations in the established “rules of thumb” for Phi or Cohen’s D
measures for their interpretation. Whilst some processes to enable conversion
between effect size statistics have been published, there is no accepted approach to
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8.3 New Learning
Overall, this research directly creates new knowledge regarding the association
between risk factors and outcomes for patients being discharged from hospital, with a
diagnosis of diabetes. The knowledge is applicable both to generalised cohorts of
patients with diabetes and specific cohorts of patients with diabetes. The first
systematic review collates knowledge and creates new learning regarding the extent
to which the research literature has described known risk factors for readmission. The
second review creates new knowledge comparing the differences in the extent of the
research literature between readmission risk factors and mortality risk factors. New
knowledge is created regarding the strengths of association between different risk
factors identifiable from a typical electronic health record for different cohorts of
patients being discharged with diabetes and in relation to different outcomes and
demonstrates the use of standardised effect sizes in this context. New knowledge is
also generated regarding the association between socioeconomic geography and
negative outcomes when patients are discharged from hospitals with diabetes.
Similarly, new knowledge is created regarding the association of glycaemic control
and time to testing with poor outcomes, when patients are discharged from hospital
with a diagnosis of diabetes. Finally, this discussion chapter presents a summarised
version of the effect size measures, noted for the diverse range of risk factors
considered within the work. The author believes this being the first example of such
an approach. This learning can help work towards identifying potential targets to
improve the readmission process for patients with diabetes as well as designing future
research projects, which are discussed later in this chapter.
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8.4 Limitations
It is important to consider the limitations of the research approach and learning,
identified here. This is, in addition, to specific limitations that have been outlined
separately in the individual chapters.
Perhaps the most important limitation of this research is the single-centre nature of the
data extraction, used to generate the results. Indeed, the readmission systematic
review identified that 41% of papers, identified in that search, were also limited to
single centre data sources. This has important implications for the research and the
findings, as it may be difficult to generalise the findings across different healthcare
organisations or different healthcare settings, nationally or internationally. To some
extent, there is some mitigation in the research approach here, given the long period
over which data was extracted (3 years) and the large number of readmissions
studied. It is also important to note that the Coventry & Warwickshire region represents
a diverse population group, which adds some robustness to the research findings.
However, it is, of course, essential however to ensure that the research findings
described here are reproducible in other healthcare settings or organisations. Indeed,
a key suggestion would be that the further work, as described below, is conducted at
a regional scale, which could indeed remain in the West Midlands region with a
collaboration between the 3 major academic NHS centres (University Hospitals
Birmingham NHS Trust, University Hospitals Coventry & Warwickshire NHS Trust &
University Hospitals of North Midlands), alongside the smaller district general
hospitals. This would encompass approximately 20 NHS sites, across this NHS region.
A similar limitation is that the data, extracted for this research, was reliant on hospital
or secondary care data. Given the nature of the research considering discharge from
hospital, this was a sensible starting point as all patients, by definition, must have been
admitted to hospital and therefore a significant amount of their data would be stored
on the hospital electronic record system. However, Community or General Practice
data may add more information and greater richness to the data used in the research
here, and would help ensure that we meet the PPI panel’s opinion that the discharge
process is a true continuum and not simply an endpoint in the inpatient care process.
Whilst widening the number of NHS organisations, contributing data to the research,
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would increase the robustness and generalisability of the results produced it is
important also to note that this would represent a significant challenge. In particular,
challenges would exist around the different ways in which data is stored and
transferred (inter-operability challenges) and challenges around variations in the
approvals processes needed to access data (information governance challenges).
Neither set of challenges are insurmountable but to include data from a large number
of secondary care organisations and access primary care datasets outside of registry
sets, such as the THIN dataset [286], would present future researchers with significant
challenges, particularly if there was an ambition to continue with anonymised datasets
for the purposes of ethical approval.
In addition to limitations around the number of sites, from which data have been
sourced, there are also limitations in terms of the dependent variables selected for
study. The combined systematic reviews identified 82 unique risk factors for
readmission, when patients are discharge from hospital with diabetes. This thesis did
not set out at any point to consider all possible risk factors, but only a selection of pre-
specified risk factors, as outlined within the Research Approach Chapter (Chapter 2)
of this thesis. This was based on both the need to keep a containable piece of work,
within which to generate meaningful and properly researched new learning, but also
based on limitations of data availability. Different electronic patient records vary in
terms of the data availability recorded within them. For example, the UHCW electronic
patient record system, used for this research, includes a comprehensive collection of
data around biochemistry (and thus Hba1c values), collected both at the hospital and
in the local community. In contrast, the electronic record includes very little information
around the medications a patient took whilst they were an inpatient, which the
systematic reviews, in chapter 3 and 4 identified as being an area of interest in relation
to mortality and readmission. This will be a future area of research as newer EHR
systems include comprehensive electronic prescribing functionalities, allowing ready
extraction and analysis of this medication related data [287].
The final limitation, which is important to discuss, is the issue around association and
causation in relation to the outcomes of interest. This PhD thesis is specifically focused
on using routinely collected electronic patient record, in order to consider associations
between potential risk factors and outcomes for patients being discharged from
hospital. The research does not look to establish a causal link between the risk factors
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and the outcome of interest. To achieve this would require a significantly different
research approach to that described here that both controls for confounders and
potentially considers a prospective study design to ensure all relevant confounder data
can be collected in structured and systematic fashion. The research must be
interpreted in this context, nevertheless, the identification of association is important
on the basis that this can form the foundation for future development of risk prediction
tools and algorithms described in more detail below.
8.5 Future Work
The data, used within this PhD, focuses specifically on numerical data. This follows
the datasets most commonly used within the systematic reviews described at the start
of the thesis. This is likely based on the relatively ease of extraction and analysis of
quantitative data from electronic health record systems. It is important to note that, in
addition to quantitative data there is a wealth of other data sources within electronic
record systems, which could be applied to the context of discharge and diabetes.
These datasets may include narrative text, (which would be important in the analysis
of discharge letters produced by clinical teams at discharge), images both from
photographs and radiological imaging datasets, as well as metadata relating to the
discharge of patients. There is undoubtedly the potential for individual (or multiple)
research projects, within each of these data types, in relation to discharge from
hospital for patients with diabetes. Whilst the analysis of such datasets may be more
complicated than quantitative data, they are readily extractable from a range of
electronic health record systems.
The final experimental chapter (chapter 7), in the thesis, noted the potential of
emerging datasets within diabetes care. These offer another source of potentially
important data, in order to understanding associations between risk factors when
patients are discharged from hospital with diabetes. The most important of these
emerging datasets is likely to be CGM based, where the blood glucose is not
measured directly, but is calculated from the glucose concentration of the interstitial
fluid around cells. CGM systems are increasing in popularity and increasingly being
recommended by policy makers, prescribed by clinicians and used by patients.
However, there exists limited research that has considered the use of CGM systems
in the inpatient environment, due to the increased costs of these systems and lack of
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integration with existing electronic patient record systems or patient monitoring
systems [288]. There are, however, a small number of studies starting to utilise data
from CGM devices in understanding risks associated with hypoglycaemia, for
inpatients with diabetes [289, 290]. The author would argue that there is the important
potential to extend such research, in order to consider the discharge process for
patients with diabetes. Indeed, as discussed in chapter 7, there is an interesting
association between “looser” diabetic controls, being protective both in the inpatient
setting and seen here is the discharge setting. Looser diabetic control effectively
means allowing a higher average blood sugar level to reduce the risk of harmful
hypoglycaemia. Data from CGM devices may help further explain why a higher Hba1c
is protective and indeed help quantify the extent to which this is being driven by
reduced levels of hypoglycaemia.
The most important direction for future work is the creation of risk prediction tools and
algorithms to support the discharge of patients with diabetes. These risk prediction
models could be embedded within electronic health record systems, and extract data
in real time to inform, both patients and clinicians, of the risks involved with an
individual patient’s discharge from hospital. By understanding which patients are at
the greatest risk, clinical teams will be able to make better informed decisions and
target interventions to those patients who need them the most. This is particularly
important in the context of limited resources, currently experienced within the NHS
context.
Risk prediction models have been developed in the context of diabetes care; typically
those that utilise electronic health record data are created using machine learning
methodologies [291]. Risk prediction models have been created in the context of
diabetes for predicting development of diabetes [291], predicting renal disease in
diabetes [292] and predicting negative cardiovascular outcomes [293].
Early models for predicting readmission, when patients are discharged from hospital
with diabetes, have been developed [294]. However, the predictive value of these
models is only moderate; for example, a model by Rubin et al has a c-statistic of 0.69,
where a value of 0.5 is considered not better a predictor than random chance [124].
One of the key challenges, with diabetes risk prediction tools, is that they fail to
rigorously pre-specify the candidate predictor variables. Therefore, this research
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thesis represents an essential first step in identifying candidate variables, both from
the published research literature and from the extraction and analysis of the data
described above. It is hoped that this research will form the foundation for future
research, which develops and validates the first United Kingdom based risk prediction
model for negative outcomes, when patients are discharged from hospital with a
diagnosis of diabetes. The development of such a tool would be essential in managing
the excess readmission rates, costs and negative experiences that this population of
patients experience each time they leave hospital and were described in such detail
during the initial patient public involvement work described in chapter 2.
8.6 Personal Concluding Remarks
The author believes this work has important implications both currently and for the
future across healthcare services, health informatics and clinical care. These
considerations are discussed below, and speculative in nature, yet are grounded on
the findings of the research described above and informed by the various Fellowship
activities described in Appendices 2-3. Despite the speculative nature of the
suggestions, the author would strongly argue that they merit further investigation and
consideration.
A) Healthcare service
This research demonstrates that routine electronic health record data for hospital
electronic record systems can be used to support the identification of patients with
diabetes discharged from hospital who are at higher risk of readmission or at higher
risk of mortality. The author would argue that stewardship of such data carries with it
the moral responsibility to ensure discharge processes and follow up plans are made
using such data and knowledge. A first step would be to present this information a
meaningful way to both patients and clinicians. This would can enable both clinicians
and patients to understand risks at an individual patient level and look to develop
mitigation measures.
In addition to presenting information about risk, healthcare organisations should look
to provide options to reduce risks in those populations suggested to be at the highest
risk. Importantly this thesis suggests that deprived populations might be amongst the
highest risk in certain circumstances.
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A challenge for healthcare services is that this information will typically cross-
organisational boundaries, with risks identified in the secondary care setting potentially
needing mitigation at the primary care level in the community. The need to cross
organisational boundaries can potentially create governance challenges, albeit these
are not unsurmountable [295]. The auth would suggest that in order to ensure
adequate data transfer to support meaningful risk prediction in primary care, that in
addition to the traditional “discharge letter” sent from hospital settings, this should
include an inter-operable data set focused around risk prediction for that individual
patient.
Finally, healthcare services must also look internationally at exemplars of how best to
support high risk populations following discharge from hospital, including in particular
wider use of tele-health and telemedicine approaches as observed in my fellowship in
the Basque Country (Appendix 3) although more typically elsewhere restricted to
surgical follow up and often still at an early stage of development [296, 297].
B) Health informatics
This thesis has important implications for health informatics. It reinforces existing
studies demonstrating the wealth of untapped information stored on electronic health
records and suitable for research similar to that described here [90, 91]. Ensuring that
such data is available and inter-operable is a key step in utilising such data sources to
promote our understanding. It is also the as future electronic health records are either
developed, or procured, that the accessibility of such data for approved research
studies is maintained, and can be readily accessed by healthcare organisation without
needing to go through EHR provider or purchase additional analytics software.
C) Clinical impact and exploitation of the results of this study
This work provides initial useful information that can potentially be incorporated into
clinical practice, whilst prospective or multicentre studies in the manner described
above are initiated. The author would argue that the most important consideration is
that both readmission and increased mortality are potentially predictable at discharge
from hospital for patients with diabetes. When discharge is planned for such patients,
it is essential that clinicians consider which patients might be at the highest level of
risk and what mitigation might be helpful to support that discharge process. This
potentially requires a shift in practices from focusing on whether a patient is “fit for
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discharge” towards whether a patient is “fit for discharge AND what might maintain
that fitness following discharge from hospital”. This thesis suggests patients who might
be at greater risk include those from deprived socioeconomic backgrounds, of older
age, using illicit substances or with deranged laboratory results. In particularly where
are relatively early check of Hba1c is planned for patients to optimise glycaemic
control, it should be considered that these patients are also at increased risk of
readmission or mortality as well as the complexities of glycaemic control. Those
patients therefore from deprived background who we would normally follow up for
assessment of glycaemic control should be the key group to whom we target additional
interventions and support.
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8.7 Conclusion
Diabetes is increasing in prevalence, internationally, and is associated with rapidly
increasing care costs. Patients with a diagnosis of diabetes in hospital are at an
increased risk of negative outcomes both during their hospital stay and following
discharge. The excess rate of readmission for patients with diabetes places a
significant burden on healthcare services, not to mention the human impact on patients
and their carers. This PhD thesis uses routinely collected electronic health record to
identify and describe associations between risk factors for negative outcomes when
patients are discharged from hospital with diabetes. The better understanding of such
associations will form the foundation for future research, which allows us to improve
patient experience, improve patient outcomes and reduce costs. The research is
focused on diabetes, being a truly data rich pathology with a wealth of readily
extractable clinical information; however, the approaches developed here can be
readily replicated for other chronic conditions to help improve healthcare systems
holistically. It is the author’s ambition that the next step in the research process is the
development of rigorous risk prediction tools that in real-time can predict the risk of
negative outcomes and thus use patient data to enable better-informed, personalised
healthcare at the point of discharge from hospital.
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Appendix 1: Raw Data Availability Statement
Data was generated from the inpatient electronic health record patient-data of
University Hospitals Coventry & Warwickshire NHS Foundation Trust. As is
typical for data sets of this nature, whilst the information is anonymised, the
ethical approval process requires analysis and storage of the raw data on secure
NHS equipment due to the risk of inadvertent or indirect breeches to
anonymization. The data is not therefore included as an appendix or
supplementary material to this thesis. The raw data may potentially be available
from University Hospitals Coventry & Warwickshire NHS Trust subject to
approval, ethical review and secure storage arrangements.
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My name is Tim Robbins, I am 29 years old, currently living in Royal Leamington Spa in the 
West Midlands. I work as an Academic Specialist Registrar in Diabetes and Endocrinology at 
University Hospitals Coventry and Warwickshire NHS Trust. I completed my pre-clinical and 
clinical training at the University of Oxford, graduating from Brasenose College initially in 2009 
with a First Class BA in Medical Science, and then with BM BCh in 2012. I completed an 
Academic Foundation Programme Training and an Academic Clinical Fellowship with Warwick 
            
graduated in 2017. I am currently jointly working at a Clinical Doctor and pursuing a PhD with 
The Institute of Digital Healthcare, part of Warwick Manufacturing Group. 
 
I am passionate about the successful adoption of digital technology into healthcare, 
particularly how to most effectively use the enormous amount of data we currently collect from 
our patients. I have been fortunate to publish research articles, present nationally and 
internationally in this area, with my current research focusing on how to most effectively utilise 
data to improve the discharge process for patients with diabetes. 
 
I am engaged to Dr Rosie Tucker, who is also a practicing doctor. Together we enjoy exploring 



































Healthcare within the United Kingdom continues to experience enormous pressure, driven 
from the increasing clinical demands of an ageing population. Healthcare as an industry has 
been slow to adopt the benefits of innovative digital technologies, often due to the complexities 
of existing non-digital systems and confidentiality concerns. Digital technologies however offer 
potentially profound benefits to healthcare systems benefitting patients, clinicians and 
healthcare organisations. The United States has invested significant resources into the 
development of digital healthcare environments and there is enormous scope for the United 
Kingdom to learn from what has worked and what has not worked so well.   
  
This Fellowship incorporated visits to The American Diabetes Association, Banner Health, 
Cerner Corporation, Harvard Medical School, Beth Israel Deaconess Medical Centre, The 
Patient Centred Outcome & Research Institute, Boston Start-up Week, MassChallenge and 
      -structured qualitative interviews 
with both the leaders and front line clinicians of these organisations six reflective themes 
considering the successful adoption of digital healthcare interventions were identified:  
A. Patient engagement in the development of digital healthcare environments B. Clinician 
engagement in development of digital health environments C. Entrepreneurship & innovation 
D. Data in digital health environments E. Informatics training pathways for clinicians F. 
Dangers of wholesale adoption of USA practices into the UK  
These themes, discussed in detail within this report supported the development of 10 key 
summary recommendations for dissemination and implementation within the United Kingdom, 
whilst offering considerable scope for further research. The key recommendations are outlined 
below and explained in more detail throughout the report:  
1. We must engage patients meaningfully in the development and delivery of digital health 
innovations and environments. Once created these digital innovations have the enormous 
potential to engage patients directly in their care, increasing quality of care and reducing costs 
of care. In achieving this we must be truly diverse in our engagement activity, being 
particularity careful to engage hard to reach groups.   
  
2. There is incredible opportunity to build emotional design into our digital innovations and 
environments, this requires considerable transparency, however the trust that is placed in UK 
clinicians provides an excellent foundation.  
  
3. As the healthcare environment becomes increasingly digital there will need to be changes 
to how generalist and specialist clinicians are trained. Frequent rotational changes will prove 
a barrier to effectively and efficiently using electronic health record systems and further 
frustrate trainees.  
  
4. Clinical informatics training pathways and clinical informatics career models are urgently 
needed, potentially developing recognition as distinct speciality within the UK Healthcare 
Environment. The Faculty of Clinical Informatics is potentially an ideal place to lead such work 
with the engagement of both trainees and patients.  
  
Page 8  
  
5. There is a need for all clinicians to have an awareness of cyber-security measures and 
contingency plans. Future informatics trainees need to have a deeper understanding built into 
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their training curricula, who may be well placed to lead in disseminating key messages to other 
trainees and clinicians.  
  
6. Clinical         -clinical ICT Leaders are 
better known to their frontline clinical staff to support engagement and communication.  
  
7. The concept of Quality Improvement Projects, completed by each individual trainee and 
assessed against fixed methodological criteria needs to be re-evaluated for a digital age, with 
a preference for collaborative working across care environments and industrial sectors.  
  
8. Work is needed to re-evaluate the research evidence hierarchy pyramid, increasing the 
value of retrospective research that can capitalise on exceedingly large diverse data sources.  
  
9. Explorative work is needed to consider the value of meta-data contained within NHS data 
sources to identify opportunities for improved care processes.  
  
10. We should capitalise on the opportunity to develop a bespoke UK digital healthcare 
environment that is developed from learning internationally but focused specifically on the 
needs of our patients and future workforce. The systems within that environment must excel 



































Why is it important? 
 
The National Health Service (NHS) in the United Kingdom faces unprecedented challenges. 
There is an increased demand for clinical care, and yet a shortage of beds to provide that care 
in. It is estimated there are a third fewer beds and yet that there were 25 years ago (Imison, 
2012) despite a 37% increase in emergency hospital admissions (Royal College of Physicians, 
2012). It is thought that a significant driver for this increased clinical demand is that our patient 
populations are getting older, with increased co-morbidities, indeed 65% of people admitted 
to hospital are now over 65 (Cornwell, 2012). This challenge is being reflected in the workforce 
with 27% of Medical Registrars (the same grade as myself) reporting that their workload is 
unmanageable (Royal College of Physicians, 2012). The General Medical Council has since 
issued guidance that healthcare in the UK       the challenge of 
matching increased demand with the supply of services and workforce. (GMC, 2017). 
 
Despite these challenges there are enormous opportunities within the NHS. More money is 
being spent on the NHS in real terms than ever in its history. We now spend an average of 
£2,160 per person, per year on health care. Whilst this is less than many other similar 
economically developed countries, it is essential to ensure this spend per capita is used in the 
most effective manner possible (NIESR, 2017). 
 
A key opportunity for healthcare is looking towards the benefits of digital health. Healthcare is 
one of the slowest industrial sectors to have adopted digital technology. In 2015 for example 
71% of all UK citizens had a smartphone and 88% of adults used the internet (Ipsos MORI, 
2015), yet just 2% of the population reported any digital transaction with the NHS (Nuffield 
Trust, 2016). There is however significant demands among the general population for access 
to digital health services  with 90% stating they would use a digital service enabling them to 
ask a clinician a question, 80% would like to view their medical records online & 60% would 
monitor their disease using a mobile app were that possible (Patient.co.uk, 2012). 
 
        ds the adoption of digital 
healthcare, there are profound benefits to the healthcare system as a whole, with the potential 
to help mitigate increasing demand and reductions in certain areas of supply. In particular 
digital health interventions can improve both the efficiency and quality of clinical care. The 
Nuffield Trust is collaboration with KPMG have clearly delineated the potential of digital health 
benefit the NHS by: (Nuffield Health, 2016): 
1. Enabling more systematic, high quality care 
2. Delivering More proactive targeted care 
3. Facilitating Better co-ordinated care 
4. Encouraging Greater patient engagement 
5. Improving resource management 
6. Delivering system learning and improvement 
If digital health interventions can support the delivery of these domains, the NHS may be able 
to continue to drive forward meeting the increasing demands of patient care, whilst maintaining 




The adoption of digital healthcare however is profoundly complex. The National Project for 
Information Technology (NpfIT) was a £10billion project aimed to achieve broad spectrum 
digital adoption, however whilst creating benefits in some areas, ultimately it failed to digitise 
the hospitals and community sectors (House of Commons Committee of Public Accounts, 
2013). The               
years resulted in some reluctance at investing further in NHS ICT systems (Syal, 2013). A key 
challenge is that the creation of a digital healthcare system is not the simple introduction of 
technology and computers,       -imagination of 
    standing how to do this effectively, and what pitfalls 
to avoid, will be critical to the successful adoption of digital healthcare to the United Kingdom. 
 
The United States has been able to advance its digital health agenda more fully than the 
United Kingdom. 46 percent of consumers are now considered active digital health adopters, 
who remarkably have used not just one, but three or more digital health tools in categories 
such as telemedicine and wearables over the course of 12 months (Tecco, 2016). 
Furthermore, in the hospital sector, the government has vigorously promoted the adoption of 
digital healthcare technologies (Harrow, 2009). The most prominent US Government 
commitment to ICT technology in healthcare was the Health Information Technology for 
Economic and Clinical Health Act (HITECH), which committed $25.9 billion to promote and 
expand the adoption of health information technology (Blumenthal, 2010). Understanding how 
this, and other digital health technology has changed the American Healthcare Environment 




The aim of this Fellowship was to spend time in diverse leading digital health organisations in 
the United States, learning about how they have successfully adopted digital health 
interventions, but also the challenges they faced. The Fellowship Activity targets how the 
understanding developed could be applied back in the United Kingdom and disseminated as 




1) Develop a detailed, hands-on understanding of the current USA digital healthcare 
environment, learning from patients, corporations clinicians and policy makers. 
2) Learn about both the opportunities and challenges encountered in developing US 
patient centred digital health systems. What would they do differently if they started 
again? 
3) Cultivate a transnational sustainable network of individuals who share these passions. 
Develop this network to share ideas, perspectives and collaborations. In sharing 
experiences there is enormous potential to benefit patients in the UK, US and 
worldwide.  
4) Widely share learning in the UK at local, regional and national levels; engaging across 
patient groups, healthcare providers, academic institutions and healthcare industries. 
5) Apply this to my own innovations and career. Achieve meaningful, measurable, 
personalised health process changes nationally. Do this at a critical time for the NHS 








The approach was to try to gain a holistic viewpoint of the adoption of digital healthcare within 
the USA, focusing particularly on diabetes as an exemplar disease, but remaining open to 
learning widely from all sources. The Fellowship was designed with the express purpose to 
understand digital healthcare adoption from the patient perspective, clinician perspective, 
   -makers perspective and corporate perspective. 
Whilst such a holistic viewpoint represents something of a challenge to achieve in the short 
Fellowship Period, it should be noted that there were significant areas of overlap. 
 
The Fellowship was designed as an explorative and reflective period rather than a formal 
research project however utilising skills developed during my  Degree I aimed to take 
a qualitative approach through structured interviews, focus groups and reflective practice. To 
encompass the above perspectives, visits were arranged in advance to The American 
Diabetes Association, Banner Health, Cerner Corporation, Harvard Medical School, Beth 
Israel Deaconess Medical Centre, and The Patient Centred Outcome & Research Institute. In 
addition during the Fellowship, I took advantage of opportunities that arose and visits were 
organised to the Boston Start-up Week, MassChallenge    
Innovation Team. 
 
The results of semi-structured interviews, observations and meetings from these events was 
recorded contemporaneously through a journal written record and then thematically appraised 






























Thematic Observations & Reflections 
 
The observations and reflections gained during the Fellowship can be grouped into 6 key 
thematic areas which are listed below, these will be explored individually and their linkages 
assessed. 
 
1) Patient engagement in development of digital healthcare environments 
2) Clinician engagement in development of digital health environments 
3) Entrepreneurship & Innovation 
4) Data in digital health environments 
5) Training for Clinicians in Informatics 
6) Dangers of wholesale adoption of USA practices into the UK 
 
1) Patient engagement in development of digital healthcare environments 
 
The Fellowship demonstrated that patient engagement in the development and delivery of 
digital healthcare environments is critical to success. In the United Kingdom the concept of 
patient engagement is certainly not new, and has been championed by the National Institute 
for Healthcare Research (NIHR, 2017). Existing UK patient engagement has however focused 
primarily on engagement with research processes, rather than engagement within the 
provision and innovation of routine healthcare services. In the USA, it is quite different, patient 
involvement is not such a requisite in research however they have explored and actively 
exploit the benefit of patient engagement in designing and developing services  for instance 
          clinical ideas and services could be 
suggested, explored and developed. 
 
The PCORI centre demonstrated how patient engagement can be achieved at varying levels 
within the delivery of a digital healthcare environment  from engagement with an individual 
patients care, to the structure of an organisation, to healthcare policy at regional or national 
levels and finally engagement during healthcare research. 
 
Digital health development benefits from patient engagement, but also can facilitate it, and 
there were case studies demonstrating the potential success of engagement at different levels. 
For example, failure to attend clinic appointments in the United States represents a major 
issue there, as it does in the UK, however using digital technologies to engage patients with 
the booking process such that they can select a preferred time and date can reduce 
significantly the number of patients who fail to attend. 
 
Central to encouraging greater patient engagement is how to effectively communicate with the 
patients you are looking to engage. An interesting case-study was that of developing text-
message adherence alerts to patients with diabetes, however pilot work demonstrated 
difficulty in deciding what wording to use for these  alerts, successful co-production with 
patients enabled a tailored wording to be created that would support, without patronising 
patients, and producing far superior results to the initial project pilot. 
 
In looking to engage patients, for instance in booking their desired clinic times through and 
on-line portal, or co-producing SMS based reminders there was something of a tendency to 
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        unwell    
              
To some extent this supports engagement as creating a consumer like environment, such as 
might be found when internet shopping, enables patients to feel more comfortable. A number 
          l consumer 
              -opening in 
that it illustrated that the assumed benefits of a normal consumer environment may not actually 
be so readily apparent. Typically when designing a digital service for consumers (e.g. an online 
shopping platform, or video on demand service) there is a desire from the designer to 
encourage consumers to both visit initially and subsequently frequently return to the digital 
service. Similarly when consumers visit these environments they want to be there often as 
part of their leisure time. In contrast healthcare is quite significantly different, patients would 
much rather not be ill, nor having to seek the advice of a healthcare profession, and the 
healthcare industry aims to reduce re-admissions and re-visits as much as possible. In 
engaging patients therefore there needs to be quite distinct process and culture compared to 
the normal consumer experience .  
 
The approach being developed by Cerner was therefore really quite refreshing and it focused 
around two key concepts. The first was designing digital environments to effectively engage 
patients through breaking health        
aim is to focus on the final patient experience, matched to what meet   
through their condition and their location of care. Overlaying this was the concept of emotional 
design, moving beyond simply digital solutions for clinical care but building emotion and 
empathy into healthcare processes. Successful emotional design they felt often relied on mere 
moments of care, however too successfully deliver those moments requires intensive pattern 
recognition based around patients individual conditions, venues and previous experiences. 
 
The delivery of emotional design within a digital healthcare environment engages patients 
strongly in their care, however requires interaction beyond simply collection of clinical facts 
such as biochemistry or radiology results. It requires patients and clinicians to engage with 
emotionally and transparently. To achieve this requires trust. The corporate environment of 
healthcare within the USA has eroded trust in healthcare professionals and therefore it is 
interesting to reflect that in the UK, where doctors represent one of the most trusted professors 
(IPSOS, 2017) it may be easier to capitalise on the profound benefits of emotional digital 
design. 
 
Whilst patient engagement and emotional design are truly exciting concepts, they are not 
without challenges. Patients are truly diverse, and successfully engaging with those patients 
requires engaging with diverse groups. The PCORI Centre highlighted that to date much of 
the patient engagement around developing digital software has been with white middle class 
Americans, rather than harder to reach populations. The American Diabetes Association have 
strong links to these harder to reach populations, who are often most in need of healthcare 
support. Some are unable to afford Insulin for themselves or their children, unable to afford 
testing strips to monitor their disease or unable to afford the healthy foods that would support 
their diabetes care. Similarly a particularly hard to reach population were the prison population 
who frequently come to The American Diabetes Association for support. These population 
groups often need written material from the American Diabetes Association and struggle to 
access digital support interventions, similarly they may struggle to have sufficient time to 
engage in the development of new digital environments, given much more pressing needs on 
their time. Time itself can be a challenge to patient engagement in the delivery of digital 
healthcare interventions. Digital technology is fast moving and the time for development (for 
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instance of a new app) can be very short before it is out-dated. The organisations I met 
therefore were trying to see how to engage patients most efficiently in development activities 
 something that still remains a major challenge. 
 
Whilst undoubtedly there are challenges to patient engagement, successfully achieving it 
should not be ignored             
            -producing digital healthcare 
environments in the UK to achieve this is an opportunity that must not be missed! 
 
2) Clinician engagement in development of digital health environments 
 
The introduction to this report highlighted the challenges faced by healthcare professionals 
working in the UK, with staff shortages and burnout being key risks. In the United States the 
retention and engagement of physicians was seen as a major priority and many were surprised 
by working practices in the United Kingdom. Just as using the development of digital 
healthcare environments to engage patients, the development of such systems to engage 
physicians can bring significant benefits. 
Electronic health record systems (EHR), which represents the digital interface clinicians use 
on a daily basis are becoming increasingly complex. There is enormous opportunity to use 
these systems to support and engage physicians. Many EHR's enable personalisation of their 
interfaces to enable clinicians to choose how information is presented to them as they log-in, 
and these interfaces can vary depending on the venue where the clinician is logging in from 
(e.g. on a ward, in a clinic or at home). Clinicians can personalise the system much more 
deeply including bespoke short-cuts and auto-filled forms, all designed to support the 
efficiency of their clinical work and the quality of care they provide. Such personalisation of 
digital systems was enormously popular with clinicians in the United Sates, however underpins 
a significant complexity of the clinical systems they are using. These systems take significant 
            -the-job- 
retention rates of physicians in US Hospitals gives the time necessary to develop an 
understanding of these systems. In the UK however junior clinicians for the first 9 years or 
more of their medical career rotate up to every 4 months, it would be impossible in this context 
for individual hospitals to engage such physicians fully in their electronic health records if they 
are moving on so frequently  this represent a major barrier to the introduction of diverse yet 
           
    t to be the digital portal that supports the care of patients, 
however in the USA they are also used to care for the clinicians. A good example of this was 
in a primary care context, where the EHR automatically tracks physicians actions. It can 
highlight to physicians themselves and their supervisors when clinicians are working 
unsustainably long hours or logging on frequently in their leisure time to catch up on work. 
This can support more effective job planning, and avoid the risks of burnout. Similarly where 
clinicians are not using the system effectively, for instance not using popular short-cuts or pre-
formatted forms the EHR can identify this and support physicians to work more efficiently. I 
            - 
amongst physicians, but quite the opposite, those I spoke to were very supportive of the 
systems they were using. 
Whilst the digital environment in the United States seemed generally popular, undoubtedly 
there remains and has previously been elements of conflict. Discussing with both the providers 
and users of the EHR systems is became apparent that when introducing new digital systems, 
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careful communication is absolutely critical. A case study is that the new systems enable 
-        suspected diagnosis for a patients is 
entered, the EHR automatically suggest which investigations should be ordered, and with as 
little as a single click, all suggested investigations can be ordered and scheduled 
automatically. To many lay readers this would seem like an ideal system, and it significantly 
reduces the risk of important investigations being omitted or forgotten. To clinicians however 
           -ruled 
and patients are not treated as individuals but rather as simply diseases. In the USA however 
they have overcome this by careful communication with the physicians involved. Rather than 
            ry clearly 
highlighted that the time saved through this approach enables more time to be spent with the 
patients identifying and supporting their emotional needs. 
Engaging physicians however went beyond simply careful wording and communication, the 
EHR systems were designed for each healthcare organisation with panels of clinicians. For 
example the reduction in variation process above requires that each diagnosed condition is 
matched to the set of investigations that are required and the urgency of those investigations 
           
             
and review the impact of any changes made. These were again popular with clinician engaging 
them directly in the digital systems. 
The Banner Health Group went yet further still and rather than simply having panels of 
clinicians inputting into the EHR design, they invested significant time and resource into 
ensuring the could engage in the most effective manner  for many clinicians this involved 
providing the time and money for them to attend mini-MBA training courses in collaboration 
with the local University. Leadership was seen to be essential to the successful delivery of 
digital interventions within this organisation, and it was noted that often ICT professionals are 
seen as being based in separate (often off-site) buildings and rarely seen on the clinical floor. 
Leadership through visibility was a major drive in the USA and it was remarkable how well the 
organisations non-clinical ICT leadership knew the clinicians delivering care on the frontline. 
This was clearly and exemplar that needs to continue to develop in the United Kingdom. 
 
3) Entrepreneurship & Innovation 
 
The presence of multiple healthcare providers within individual US cities promotes 
competition. This is competition for attracting patients, recruiting staff members and listing 
insurers. Such competition drives innovation across care and increasingly digital innovation is 
at the forefront of such changes. Furthermore the corporate nature of healthcare within the 
United States has promoted a strong entrepreneurial ethos with individual healthcare 
organisations small and agile enough to reach out to entrepreneurs to create digital 
interventions and deliver digital health based change. 
 
There is a strong innovation ethos within healthcare in the United Kingdom, this is driven 
          innovation 
and entrepreneurial approaches observed in the USA. In the UK every trainee is expected 
annually to complete a Quality Improvement project, this is expected to follow a set Quality 
Improvement methodology and is assessed as part of their annual competency reviews. 
Digital Health Innovation in the USA takes a significantly different approach, the projects 
            
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providers, digital health corporations, patient groups and public sector organisations. The 
players within the originating healthcare organisation are diverse and work in truly 
collaborative relationships. Digital Health innovation necessarily requires this approach, as a 
diverse range of skillsets are required including clinical, managerial, information technology 
and data science. 
 
The selection of which processes to innovate was also important, in the United Kingdom 
innovation and quality improvement is often borne out of clinicians frustrations with existing 
systems, however my experiences in the USA suggested that might not be the most effective 
approach to achieving change. The Pulse@MassChallenge Public Private Partnership is a 
remarkable organisation supported by the local equivalent of a City Council to encourage 
          
and entrepreneurs who suggest innovations and apply for funding from the original healthcare 
organisation. The Pulse@MassChallenge then provide support to the selected teams to 
deliver their change effectively and efficiently. This approach identifies that in the challenging 
healthcare environment, to be truly successful digital innovations need to do more than just 
save money or improve care, but simultaneously need to address strategic challenges of 
importance to healthcare leadership teams. It should be noted that the Academic Health 
Science Networks in the United Kingdom have the potential to develop similar pathways and 
approaches as Pulse@MassChallenge and truly make the United Kingdom a leader in Digital 
Health Innovation. 
 
                
approach to digital health innovation. This may be something that has for some time been lost 
in the NHS due to budget constraints or the fallout from the National Programme for 
Information Technology described above. A good example of this was the Remote Operations 
Systems at the Banner Hospital Group where Intensive Care Units across the country are 
linked by in-room video-        
Here Critical Care Outreach Nurse Practitioners and Intensive Care Physicians provide 
remote management advice to these locations supported by staff on-site. This enables rapid 
deployment of highly specialist nursing and medical expertise into centres that would not 
otherwise be able to benefit. The real-time management of acutely unwell patients, right 
through to managing cardiac-arrest situations remotely was remarkable to see and a clear 
demonstration of what can be achieved with digital health innovation. 
 
The creation of digital health environments within US Healthcare systems itself provided an 
opportunity for innovation of wider healthcare processes. The implementation of electronic 
healthcare records can either be modelled against existing workflows or be used to create 
transformation. Modelling against existing systems reduces activation energy, reduces cost, 
and can be standardised across healthcare organisations, however potentially loses an 
             -
         -   
change. Such approaches can represent substantially more change than an organisation can 
handle and have serious repercussions. An alternative approach is that as digital systems are 
developed, the underlying processes they are applied to are assessed and modifications occur 
gradually in tandem. A good example of this is in the Banner Health Group where the 
introduction of digital systems identified delays in getting blood test results back and X-rays 
performed was delaying care. As a consequence the workflow was modified so that patients 
bloods are taken at 4am and X-rays performed at 6am so that all information is available for 
the morning ward round. The opportunity to be discharged from hospital earlier is a sufficient 
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driver for patients to accept being woken so early in the morning and the cost savings of early 
discharges readily accommodate the costs of employing staff out of hours. 
 
Undoubtedly the organisations visited suggest digital health innovation and entrepreneurship 
is becoming increasingly successful in the United States. In discussions with US practitioners 
as to how digital innovation can be promoted in the UK, there was an interesting insight that 
all too frequently the risk of doing nothing is an organisational risk, and yet the risk of doing 
something is a personal risk. Moving away from innovation as an individual project, but rather 
a collaborative effort has enormous potential to overcome this seeming paradox. 
 
4) Data in Digital Health Environments 
 
Creating successful digital health environments is dependent on handling increasingly large 
quantities of complex data. The United Kingdom is in a very fortunate position to be able to 
utilise the data we already collect on patients, based on the fact that the NHS identifies each 
patient with a unique identifier (the NHS Number). This is an enormous benefit to healthcare 
in this country and should not be overlooked  it certainly created a significant amount of envy 
in the United States where patients may have unlinked records with different healthcare 
records with different providers across the state, country or even within the same city. Whilst 
the UK potentially has a head start in the effective use of healthcare data, there is a significant 
potential to learn collaboratively from approaches trialled in the USA. 
Central to the effective use of data in healthcare, is the development of effective electronic 
health records. Electronic health records act as both the interface to clinical data repositories 
but also act as the broker between different clinical processes, and business systems. The 
HITECH Acts described above in the USA were critical to the implementation of USA systems 
and the Meaningful Use Certification further drives standards. The failure of the National 
Programme for ICT in the UK means we have not benefited from universal high quality 
           
development of such systems. 
Within the modern healthcare environment using data effectively requires the ability to manage 
both transitions of care, but also transitions of data. For instance the transition of data between 
different clinical systems, between different hospitals, or between primary and secondary care. 
Increasingly the boundaries of healthcare care are becoming more blurred, with patients 
wishing to utilise their data on third party devices or apps, or add their own data to the 
healthcare record. It is important to recognise therefore that as the UK proceeds to procure 
new Electronic Health Records that they are able to integrate and effectively transition 
                
ability to integrate with external apps and services, rather than their usefulness as 
comprehensive yet closed platforms. It is quite exciting to note that healthcare data systems 
in the USA have historically been provided by specialist companies due to the complexities of 
    hough non specialist digital companies 
such as Apple or Google were reported to be actively pursuing HIPPA Compliance, potentially 
dramatically changing the digital healthcare landscape of the future.  
Increasing the storage and accessibility of data to patients and clinicians whilst transitioning 
this data across boundaries introduces significant cyber security concerns. My Fellowship 
travels coincided with the recent WannaCry Ransomware attack that compromised a number 
of NHS ICT systems nationally, and prompted far more to be shut down to prevent infection 
or attack (NAO, 2017). At Harvard Medical School, discussions on cyber security noted that 
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the typical refresh rate for medical computer equipment is very different to non-medical 
equipment and that unfortunately many ICT systems that were affected had failed to install 
security upgrade patches. In the USA due to the wider installation of these patches only 2 
hospitals were affected. Nevertheless cyber security remains a major concern for USA 
healthcare networks, who were much more affected by the Petia Virus attack, not because 
their own systems were affected but because supplier systems often based in the Ukraine 
were profoundly impaired. 
It was clear that US Healthcare Leadership now sees virus attacks as a part of life, and likely 
to increase in the future. The risk is substantial and if a ransomware attack was to encrypt 
patient information it would be impossible to identify if that patient information had been 
moved. Despite this, the suggestion was that a pervasive ransomware attach was only a 
matter of time and preparedness was key. Healthcare organisations need to consider not just 
how they would recover, but how they would recover safety critical systems quickly, and 
achieve speed that whilst protecting their back-up environments (which should those be 
compromised would prove catastrophic). The recent cyber-attacks however have increased 
the focus on cyber security both for healthcare leaders in the USA, but also training for 
clinicians on the ground and changes to working practices. It is important that the UK builds 
experience along with our USA counter-parts and I would argue there is significant education 
             -your-
de             , 
may add substantial cyber-          
be taken into account. 
Whilst there are substantial fears and concerns regarding the risks of increasing healthcare 
data availability and accessibility, the potential of such sources to benefit our understanding 
of health and disease is enormous. In particular risk-prediction modelling using large 
healthcare data sets is transforming understanding of disease and healthcare processes. 
Notable approaches that were being taken in the USA included automatic, continuous risk 
stratification to enable personalised care throughout a healthcare journey, rather than the 
  isk stratification that is often applied in the UK. Furthermore using large data 
sets incorporating non-clinical data was vital, there is an underused treasure trove of so called 
- -data is effectively data that sits around a data-point of initial interest; for 
instance a blood sugar value is a data point of interest, however meta data includes; who 
entered the value into the system, what time it was entered, how many times it was reviewed, 
who reviewed it and what actions did users take after reviewing the value. Incorporating meta-
data into the ideas described above of emotional or quasi-emotional data collection has 
enormous research potential. 
When considering the research potential of the health data that is increasing in quantity, quality 
and accessibility, it worth noting that our attitudes to research may need to change. Historically 
there has been an evidence based hierarchy of research evidence (Petrisor, 2007) with 
individual case studies at the bottom, followed by retrospective reviews of data a little higher, 
             
top of the pyramid for their ability to consider causality. This pyramidal structure however was 
conceived when there was far less data availability, where retrospective data was collected 
by hand from paper records, not the automated collection of enormous quantities of clinical 
data and meta-data across care boundaries and indeed beyond. Whilst retrospective data 
remains unable to identify causality such a powerful resource should not be overlooked and 
there is a need to reconsider the concept of a pyramid of importance, but rather the concept 
of different research approaches being optimised for different research questions, and true 
value coming when they are combined. 
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5) Training for Clinicians in Informatics 
There are clear benefits to the delivery of innovative digital health environments and effective 
use of healthcare data. The observations discussed already however highlight that to achieve 
this is complex, requiring collaborations across industries, with patients, incorporating cyber 
security and meaningful innovation pathways. To meet these complex demands it is essential 
that there is a clinical workforce well versed in the language, skills and experience needed to 
manage such interventions and to facilitate patient co-production & engagement.  
The USA have recognised clinical informatics as a dedicated healthcare speciality. Clinical 
informatics can be defined as the transformation of healthcare by analysing, designing, 
implementing and evaluating information and communication systems to improve patient care 
and access to care. Clinicians training in informatics in the USA spend roughly 30% of their 
time on clinical elements and 70% on informatics elements. At the Beth Israel Medical Centre 
there were 8 informatics fellows. There is an established career path with a defined syllabus, 
accrediting exams and then expectations that trainees will progress to Assistant Chief Medical 
Informatics Officers and subsequently Chief Medical Informatics Officers Roles. The 
Informatics training fellows are a truly valuable resource to the organisations that employ them, 
often acting as an in-house consulting team for digital health innovation and strategic delivery. 
I was fortunate to spend time discussing Clinical Informatics Training with Professor Charles 
Safran, who is the Chief of Division at the Beth Israel Hospital & Harvard Medical School, as 
well as the immediate past president of the American Medical Informatics Association. His 
feeling was that establishing informatics as clinical speciality substantially changed 
perceptions regarding the role of informatics in healthcare both for trainees and informaticians 
themselves. During our discussions however it was clear that the training pathway adopted in 
the USA, might not be the most appropriate pathway to adopt in the UK given differences in 
clinical training internationally. 
Within the UK there is no distinct training programme, although the role of the Chief Clinical 
              -
the-            
Summer School (RCP, 2017). There is clearly a need to provide those already in post with 
training, however I would argue a pressing need to ensure training can be delivered in a 
structured way throughout existing training time for trainees wishing to take up CCIO or similar 
posts in the future. The Faculty of Clinical Informatics is an organisation being established 
within the United Kingdom that looks to be a Professional Membership Body for all clinical 
informatics professionals across the UK. It aims to publish professional standards, support re-
validation, provide accreditation and promote professional leadership. It has just appointed is 
Founding Fellows, first members of staff and held its first meeting. There is enormous potential 
of this Faculty to support the delivery of a clear training pathway for clinical informatics trainees 
from medical school to consultant level. Enabling sustainable, rigorous and recognised 
informatics training within the UK workforce will be essential to the successful delivery of digital 
healthcare environments for our future patients and the USA provides an excellent example 







6) Dangers of wholesale adoption of USA practices into the UK 
Throughout this Fellowship report it is evident that there is enormous potential to learn from 
innovative practice that certain centres in the USA have adopted. It must be warned however 
that the wholesale adoption of USA practices with regard to digital health innovation should 
not be taken without due assessment. A good example is given above, whereby the concept 
of rigorous informatics training and career pathways is invaluable, differences between 
existing USA & UK medical training mean that in practice a successful UK pathway would look 
really quite different. 
The importance of rigorously assessing concepts and products developed in the United States 
before adopting similar in the UK goes beyond simply training. The Electronic Health Records, 
which are at the centre of many Digital Health interventions in the United States were built as 
a consequence of the HITECH Act and are certified against Meaningful Use Criteria. The 
HITECH Act and Meaningful Use Criteria were designed with the needs of the American 
Health System in mind, this is profoundly different to the UK Health System. Adopting too 
readily Ameri     wrongly adopting the criteria set out by 
            
       is admitted, treated and discharged rather than a 
care journey from birth to death as would be achievable in the United Kingdom. The reasoning 
behind this is that in the USA healthcare providers bill insurers based around the costs of each 
episode of care, and therefore the digital systems is created to reflect that. We would 
potentially look to create something quite different in the UK. 
Whilst this is something of a cautionary note, it is actually potentially one of enormous 
optimism, giving the opportunity to create something in the UK that is truly bespoke for our 
              
on the work done in the USA and internationally, alongside many of the successful products 
that have been developed in the USA however engaging UK patients, UK clinicians and UK 
trainees to assessing and adapting those products will be essential to the future delivery of 


















1. Clinicians & academics must engage patients meaningfully in the development and 
delivery of digital health innovations and environments. Once created these digital 
innovations have the enormous potential to engage patients directly in their care, 
increasing quality of care and reducing costs of care. In achieving this we must be truly 
diverse in our engagement activity, being particularity careful to engage hard to reach 
groups.  
 
2. There is incredible opportunity to build emotional design into our digital innovations 
and environments, this requires considerable transparency, however the trust that is 
placed in UK clinicians provides an excellent foundation. 
 
3. As the healthcare environment becomes increasingly digital there will need to be 
changes to how generalist and specialist clinicians are trained, this will need to 
be addressed by bodies such as Health Education England responsible for training. 
Frequent rotational changes will prove a barrier to effectively and efficiently using 
electronic health record systems and further frustrate trainees. 
 
4. Clinical informatics training pathways and clinical informatics career models are 
urgently needed, potentially developing recognition as distinct speciality within the UK 
Healthcare Environment. The Faculty of Clinical Informatics is potentially an ideal place 
to lead such work with the engagement of both trainees and patients. 
 
5. There is a need for all clinicians to have an awareness of cyber-security measures 
and contingency plans, this can be developed during both undergraduate and 
postgraduate training. Future informatics trainees need to have a deeper 
understanding built into their training curricula, who may be well placed to lead in 
disseminating key messages to other trainees and clinicians. 
 
6.          non-clinical ICT Leaders 
are better known to their frontline clinical staff to support engagement and 
communication. 
 
7. The concept of Quality Improvement Projects, completed by each individual trainee 
and assessed against fixed methodological criteria needs to be re-evaluated for a 
digital age, with a preference for collaborative working across care environments and 
industrial sectors. 
 
8. Work is needed to re-evaluate the research evidence hierarchy pyramid, 
increasing the value of retrospective research that can capitalise on exceedingly large 
diverse data sources. 
 
9. Explorative work is needed to consider the value of meta-data contained within NHS 
data sources to identify opportunities for improved care processes. 
 
10. Clinicians & Academics should capitalise on the opportunity to develop a bespoke UK 
digital healthcare environment that is developed from learning internationally but 
focused specifically on the needs of our patients and future workforce. The systems 
within that environment must excel at transferring data across boundaries 
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Dr Tim Robbins visited the Kronikgune Institute in the Basque Country, Spain. The aim of his visit was to better 
understand Basque Country  and to apply 
this learning in the context of UK & international diabetes care. The Basque Country has received special recognition 
for it receiving a 4-star accreditation 
of it approach. The Kronikgune Institute aims to promote and carry out research into the management and 
organisation of health and social-care services, in line with the policies of the department responsible for health, which 
pursue the continuous adaptation and transformation of the health system, keeping people at the centre of the system 
and including the challenges arising from old age, chronicity and dependency.  
 
The learning from the fellowship period can be most succinctly summarised into three overarching themes; (1) a 
clearly defined health policy that pushes boundaries (2) repeated population wide risk stratification (3) E-health 
strategies. This report defines the achieved learning under each of these three categories and then describes how this 
knowledge and the techniques  described can be incorporated or integrated into diabetes research and diabetes 
practice innovation in the NHS Context and internationally. 
Health Policy that Pushes Boundaries 
Basque country health reforms are credited with development of one of the most successful integrated care strategies 
in Europe. These reforms are based on 
Basque Country 2013-2020  (HPBC). NHS has also stressed the need for effective integrated care to manage 
chronic disease and multi-morbidity. The NH  (LTP), 
released January 2019. The effectiveness of the LTP 
to deliver effective integrated care. There is however significant contrast between HPBC (proven highly effective in 
practice) and the new LTP. Development of both policies took a similar approach of cross-sector engagement. Both 
approaches stress significant baseline progress already made in life expectancy, efficiency and outcomes, whilst 
recognising chronic disease challenges. There are similar focuses on priority diseases including diabetes, cancer, 
obesity, domestic violence and mental health. 
A crucial difference is that HPBC outlines conceptual frameworks on which service transformation is based. The 
frameworks cover health, social determinants and implementation. The LTP does not reframe the conceptual 
framework, and whilst reduction of health inequality features heavily, it t have the same prominence. In 
contrast the LTP focuses more on leveraging digital health interventions. 
Building on the Basque conceptual frameworks there is the establishment of health as a personal asset and a 
macroeconomic factor. There is a far stronger focus on civic co-responsibility . This extends to the Basque "Health in 
All Policies" approach demanding support from other social structures, whilst the LTP in contrast looks outwards 
explaining how it  
A key contrasts is structured and itemised listing of quantitative indicator goals comparing status quo with 
end-of-plan targets, this includes health outcomes, core structural and intermediate determinants. The LTP expresses 
no such quantitative targets, but does include financial targets. 
Both healthcare systems therefore outline ambitious plans for development of sustainable integrated care. The 
Basque model is centred on conceptual frameworks and an overriding focus on health inequalities alongside 
quantitative outcome targets. The LTP acknowledges the importance of inequality and focuses more on digital delivery 
of economically sustainable integrated care. It will be important to evaluate progress against these aims alongside the 
next iteration of the Basque Health Plan in 2020.  
 
  
Population Wide Risk Stratification 
The Basque country have adopted a process of regular population wide risk stratification with ordering of the 
population according to their expected healthcare need over the next year. To achieve this, healthcare cost is used as 
a proxy of healthcare need and uses a commercial model provided by John Hopkins University. The use of a universal 
country-wide integrated electronic health record enables data to be pulled from primary care secondary care tertiary 
care and community pharmacy data for the entire population. This creates a pyramid traffic-light based summary of a 
patients predicted healthcare cost. Importantly, linear regression not black box artificial intelligence is used in order 
to ensure acceptability to clinicians using the tools. There still however remain some concerns regarding the use of 
cost as an outcome and  based on the formula; (Individual 
Predictive Cost)/(Average Basque Cost). 
At the core of risk stratification is a focus on multi-morbidity, with the top of the risk stratification pyramid dominated 
by patients with multi-morbidity. Within this multi-morbidity process there is specific inclusion and consideration of 
patients with diabetes, with 140,000 patients with diabetes identified in the Basque Country. The risk stratification 
process for diabetes patients focuses on whether or not the patient has had a recent hba1c and what that hba1c is. 
The output of the risk stratification process is an alert within the country-wide electronic health record (EHR) and a 
reason for that scoring directly visible within the EHR. There are 16,000 patients in the highest red category. These 
patients benefit from dedicated high risk patient pathways that support patients both in the community and on 
admission to hospital. Importantly, clinicians can add patients to directly to these high risk pathway regardless of the 
automated risk stratification process therefore blending clinical judgement with quantitative risk stratification. 
E-Health Strategies 
Central to both the Basque Health Policy and the Risk Stratification approach is a highly developed digital health 
ecosystem that directly benefits patients with chronic disease and multi-morbid conditions such as diabetes. This is 
underpinned by a country-wide electronic health record called Osabide, which crosses primary care, secondary care, 
community care and pharmacy based care. This health record includes remarkable digital health interventions for 
example a social prescribing module that allows communities to collect and input social prescribing opportunities, 
which can then be digitally prescribed to patients through the EHR itself. The centrepiece to the digital health strategy 
of the Basque Country is their E-health centre. This E-health Centre is housed alongside the emergency services and 
staffed primarily by nurses with a comprehensive collection of high quality digitally stalled protocols. What is 
remarkable about the e-health centre is that (unlike services such as NHS 111) this service is fully integrated meaning 
not only does it deal with urgent patient calls 24/7/365 on an adhoc basis, however it also enables scheduled calls and 
interventions across almost all disease areas within the Basque Country. This means that, for example, when a patient 
leaves a hospital setting with a diabetes diagnosis the hospital team can communicate this to the e-health central 
team, who from this central location, will call the patient, identify how they are getting on and suggest potential 
changes. The reverse integration also exists and is regularly used, whereby the e-health centre are empowered directly 
to book patients into specialist follow up clinics where they feel there is an urgent need, without having to go through 
a referral or approval process. The service is highly efficient in reducing unnecessary secondary care follow ups or 
hospital admissions and itself handles approximately 180,000 patient contacts over a 1 year period. 
Summary 
Diabetes is a chronic condition that increasingly co-exists with other medical conditions in our era of multi-morbidity 
medicine. It is therefore essential that we develop and design integrated healthcare systems to support patients with 
diabetes and other multi-morbidity conditions. The Basque Country represents and ideal living lab where organisations 
such as Kronikgune have been highly effective in developing and piloting integrated care strategies. My own PhD work 
in predicting complications when patients with diabetes leave hospital has been directly influenced by these 
experiences, in particular considering the techniques and approaches needed to effectively implement such risk 
stratification in the clinical environment. Furthermore, the approaches to digital health interventions and health policy 
development are directly relevant to the UK and international environment. To share this work further we have 
submitted a collaborative abstract to the International Conference on Integrated Care 2020, and are working 
collaboratively on 2 journal articles for submission to peer reviewed journals in the coming months.  
Most importantly I would like to thank Dr Esteban De Manuel and his team for so kindly hosting me at Kronikgune 
and The EFSD for providing the financial support to achieve this Fellowship and associated learning opportunities. 
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SpR in Endocrinology  
 
University Hospitals Coventry & Warwickshire 




Dear Timothy Robbins  
 
Study Title: Analysing the Risk of Readmission for Patients with Diabetes 
Discharged from Hospital 
 
Study Ref:  GF0220 
 
Thank you for sending in the required documents and completing the GafREC form for the 
above study. Having reviewed the details of your proposed project, research involving 
previously collected, non-identifiable information including research undertaken by staff 
within a care team using previously collected information during the course of care of their 
own patients or clients, are excluded from NHS Research Ethics Committee (REC) review 
therefore; I can confirm that we are happy for you to carry out this project within UHCW 
NHS Trust.  
 
Please be aware that should you wish to change the project in anyway, you must notify our 
office using the above reference. 
 
I have logged your study on behalf of the Trust, which means you can proceed. I wish you 
every success with your project.  
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University Hospitals Coventry & Warwickshire NHS Trust 
4th  Floor Rotunda, ADA40017 
University Hospital 
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Dr Tim Robbins 
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26 November 2017 
 
 
Dear Dr Tim Robbins 
 
Study Title and BSREC Reference: Analysing the Risk of Readmission for Patients with 
Diabetes Discharged From Hospital REGO-2017-2114 
 
 
Thank you for submitting the revisions to the above-named study to the University of 
      -Committee for approval.   
 
I am pleased to confirm that approval is granted and that your study may commence. 
 
             
Research Data Management Policy, details of which may be found on the Research and 
            




           Information Classification 
and Handling Procedure          
       Information Classification and 
  at: 
http://www2.warwick.ac.uk/services/gov/informationsecurity/handling. 
Investigators should familiarise themselves with the classifications of information defined 





Handling Electronic Information: 
http://www2.warwick.ac.uk/services/gov/informationsecurity/handling/electronic/ 




Please also be aware that BSREC grants ethical approval for studies. The seeking and 
obtaining of all other necessary approvals is the responsibility of the investigator. 
 




Biomedical and Scientific 
Research Ethics Sub-Committee 
Research & Impact Services 
University of Warwick 






1. Any necessary agreements, approvals, or permissions required in order to comply 
      gulations and Procedures. 
2. Any necessary approval or permission required in order to comply with the University 
         
the governance, acquisition, storage, use, and disposal of human samples for 
research. 
3. All relevant University, Faculty, and Divisional/Departmental approvals, if an 
employee or student of the University of Warwick. 
4.          
appropriate), if a student of the University of Warwick. 
5. NHS Trust R&D Management Approval, for research studies undertaken in NHS 
Trusts. 
6. NHS Trust Clinical Audit Approval, for clinical audit studies undertaken in NHS 
Trusts. 
7. Approval from Departmental or Divisional Heads, as required under local procedures, 
within Health and Social Care organisations hosting the study. 
8. Local ethical approval for studies undertaken overseas, or in other HE institutions in 
the UK. 
9. Approval from Heads (or delegates thereof) of UK Medical Schools, for studies 
involving medical students as participants. 
10. Permission from Warwick Medical School to access medical students or medical 
student data for research or evaluation purposes. 
11. NHS Trust Caldicott Guardian Approval, for studies where identifiable data is being 
transferred outside of the direct clinical care team. Individual NHS Trust procedures 
vary in their implementation of Caldicott guidance, and local guidance must be 
sought. 
12. Any other approval required by the institution hosting the study, or by the ap
employer. 
 
There is no requirement to supply documentary evidence of any of the above to BSREC, but 
applicants should hold such evidence in their Study Master File for University of Warwick 
auditing and monitoring purposes. You may be required to supply evidence of any 
necessary approvals to other University functions, e.g. The Finance Office, Research & 
Impact Services (RIS), or your Department/School. 
 
May I take this opportunity to wish you success with your study, and to remind you that any 
Substantial Amendments to your study require approval from BSREC before they may be 









Dr David Ellard 
Chair 
Biomedical and Scientific 
Research Ethics Sub-Committee
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